BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008;295:G987-95. [PMID: 18772365 DOI: 10.1152/ajpgi.90272.2008] [Cited by in Crossref: 305] [Cited by in F6Publishing: 290] [Article Influence: 20.3] [Reference Citation Analysis]
Number Citing Articles
1 Luo Y, Woodie LN, Graff EC, Zhang J, Fowler S, Wang X, Wang X, O'Neill AM, Greene MW. Role of liquid fructose/sucrose in regulating the hepatic transcriptome in a high-fat Western diet model of NAFLD. J Nutr Biochem 2023;112:109174. [PMID: 36280127 DOI: 10.1016/j.jnutbio.2022.109174] [Reference Citation Analysis]
2 Flessa CM, Nasiri-Ansari N, Kyrou I, Leca BM, Lianou M, Chatzigeorgiou A, Kaltsas G, Kassi E, Randeva HS. Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research. Int J Mol Sci 2022;23. [PMID: 36555433 DOI: 10.3390/ijms232415791] [Reference Citation Analysis]
3 Jiaxin H, Zhu C, Jing Y, Qianhui S, Fuqian J, Qiyuan P, Yi L, Jukun S. Plasma elaidic acid level is associated with periodontal health in American adults: A cross-sectional study. Front Nutr 2022;9:1034841. [PMID: 36570162 DOI: 10.3389/fnut.2022.1034841] [Reference Citation Analysis]
4 Fornari F, Giovannini C, Piscaglia F, Gramantieri L. Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research. JHC 2022;Volume 9:1263-1278. [DOI: 10.2147/jhc.s347946] [Reference Citation Analysis]
5 Gallage S, Avila JEB, Ramadori P, Focaccia E, Rahbari M, Ali A, Malek NP, Anstee QM, Heikenwalder M. A researcher's guide to preclinical mouse NASH models. Nat Metab 2022;4:1632-49. [PMID: 36539621 DOI: 10.1038/s42255-022-00700-y] [Reference Citation Analysis]
6 Zheng S, Yang W, Yao D, Tang S, Hou J, Chang X. A comparative study on roles of natural killer T cells in two diet-induced non-alcoholic steatohepatitis-related fibrosis in mice. Ann Med 2022;54:2233-45. [PMID: 35950602 DOI: 10.1080/07853890.2022.2108894] [Reference Citation Analysis]
7 Phung HH, Lee CH. Mouse models of nonalcoholic steatohepatitis and their application to new drug development. Arch Pharm Res 2022. [DOI: 10.1007/s12272-022-01410-5] [Reference Citation Analysis]
8 Magee N, Ahamed F, Eppler N, Jones E, Ghosh P, He L, Zhang Y. Hepatic transcriptome profiling reveals early signatures associated with disease transition from non-alcoholic steatosis to steatohepatitis. Liver Research 2022. [DOI: 10.1016/j.livres.2022.11.001] [Reference Citation Analysis]
9 Leslie J, Mackey JBG, Jamieson T, Ramon-Gil E, Drake TM, Fercoq F, Clark W, Gilroy K, Hedley A, Nixon C, Luli S, Laszczewska M, Pinyol R, Esteban-Fabró R, Willoughby CE, Haber PK, Andreu-Oller C, Rahbari M, Fan C, Pfister D, Raman S, Wilson N, Müller M, Collins A, Geh D, Fuller A, McDonald D, Hulme G, Filby A, Cortes-Lavaud X, Mohamed NE, Ford CA, Raffo Iraolagoitia XL, McFarlane AJ, McCain MV, Ridgway RA, Roberts EW, Barry ST, Graham GJ, Heikenwälder M, Reeves HL, Llovet JM, Carlin LM, Bird TG, Sansom OJ, Mann DA. CXCR2 inhibition enables NASH-HCC immunotherapy. Gut 2022;71:2093-106. [PMID: 35477863 DOI: 10.1136/gutjnl-2021-326259] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
10 Liu J, Yao B, Gao L, Zhang Y, Huang S, Wang X. Emerging role of carboxylesterases in nonalcoholic fatty liver disease. Biochem Pharmacol 2022;205:115250. [PMID: 36130649 DOI: 10.1016/j.bcp.2022.115250] [Reference Citation Analysis]
11 Chehade SB, Green GBH, Graham CD, Chakraborti A, Vashai B, Moon A, Williams MB, Vickers B, Berryhill T, Van Der Pol W, Wilson L, Powell ML, Smith DL Jr, Barnes S, Morrow C, Mukhtar MS, Kennedy GD, Bibb JA, Watts SA. A modified standard American diet induces physiological parameters associated with metabolic syndrome in C57BL/6J mice. Front Nutr 2022;9:929446. [PMID: 36105576 DOI: 10.3389/fnut.2022.929446] [Reference Citation Analysis]
12 Qiao P, Jia Y, Ma A, He J, Shao C, Li X, Wang S, Yang B, Zhou H. Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice. Front Pharmacol 2022;13:934136. [DOI: 10.3389/fphar.2022.934136] [Reference Citation Analysis]
13 Rodríguez-fragoso L, Rodríguez-lópez A, Sánchez-quevedo J. Models of Hepatotoxicity for the Study of Chronic Liver Disease. Animal Models and Experimental Research in Medicine [Working Title] 2022. [DOI: 10.5772/intechopen.106219] [Reference Citation Analysis]
14 Lee M, Park S, Xu Y, Kim J, Han H, Lee J, Paik JK, Lee H. Ethanol Extract of Pinus koraiensis Leaves Mitigates High Fructose-Induced Hepatic Triglyceride Accumulation and Hypertriglyceridemia. Applied Sciences 2022;12:6745. [DOI: 10.3390/app12136745] [Reference Citation Analysis]
15 Vetuschi A, Cappariello A, Onori P, Gaudio E, Latella G, Pompili S, Sferra R. Ferroptosis resistance cooperates with cellular senescence in the overt stage of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Eur J Histochem 2022;66. [PMID: 35726536 DOI: 10.4081/ejh.2022.3391] [Reference Citation Analysis]
16 Bathish B, Robertson H, Dillon JF, Dinkova-Kostova AT, Hayes JD. Nonalcoholic steatohepatitis and mechanisms by which it is ameliorated by activation of the CNC-bZIP transcription factor Nrf2. Free Radic Biol Med 2022;188:221-61. [PMID: 35728768 DOI: 10.1016/j.freeradbiomed.2022.06.226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Lee GR, Lee HI, Kim N, Lee J, Kwon M, Kang YH, Song HJ, Yeo CY, Jeong W. Dynein light chain LC8 alleviates nonalcoholic steatohepatitis by inhibiting NF-κB signaling and reducing oxidative stress. J Cell Physiol 2022. [PMID: 35696549 DOI: 10.1002/jcp.30811] [Reference Citation Analysis]
18 Moradi F, Moosavian SP, Djafari F, Teimori A, Imani ZF, Naeini AA. The association between major dietary patterns with the risk of non-alcoholic fatty liver disease, oxidative stress and metabolic parameters: A case-control study. J Diabetes Metab Disord 2022;21:657-67. [PMID: 35673496 DOI: 10.1007/s40200-022-01028-w] [Reference Citation Analysis]
19 Varani J, McClintock SD, Knibbs RN, Harber I, Zeidan D, Jawad-Makki MAH, Aslam MN. Liver Protein Expression in NASH Mice on a High-Fat Diet: Response to Multi-Mineral Intervention. Front Nutr 2022;9:859292. [PMID: 35634402 DOI: 10.3389/fnut.2022.859292] [Reference Citation Analysis]
20 Hamada S, Takata T, Yamada K, Yamamoto M, Mae Y, Iyama T, Ikeda S, Kanda T, Sugihara T, Isomoto H. Steatosis is involved in the progression of kidney disease in a high-fat-diet-induced non-alcoholic steatohepatitis mouse model. PLoS One 2022;17:e0265461. [PMID: 35294499 DOI: 10.1371/journal.pone.0265461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Jin P, Qi D, Cui Y, Lenahan C, Deng S, Tao X, Duris K. Activation of LRP6 with HLY78 Attenuates Oxidative Stress and Neuronal Apoptosis via GSK3β/Sirt1/PGC-1α Pathway after ICH. Oxidative Medicine and Cellular Longevity 2022;2022:1-18. [DOI: 10.1155/2022/7542468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Saliu TP, Kumrungsee T, Mitsumoto K, Chen S, Yanaka N. Satellite cell content and muscle regeneration in a mouse model of NAFLD. Nutrition 2022;96:111570. [DOI: 10.1016/j.nut.2021.111570] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Talenezhad N, Mirzavandi F, Rahimpour S, Amel Shahbaz AP, Mohammadi M, Hosseinzadeh M. Empirically derived dietary pattern and odds of non-alcoholic fatty liver diseases in overweight and obese adults: a case-control study. BMC Gastroenterol 2022;22:158. [PMID: 35354433 DOI: 10.1186/s12876-022-02222-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Song JX, An JR, Chen Q, Yang XY, Jia CL, Xu S, Zhao YS, Ji ES. Liraglutide attenuates hepatic iron levels and ferroptosis in db/db mice. Bioengineered 2022;13:8334-48. [PMID: 35311455 DOI: 10.1080/21655979.2022.2051858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Martin-Grau M, Marrachelli VG, Monleon D. Rodent models and metabolomics in non-alcoholic fatty liver disease: What can we learn? World J Hepatol 2022; 14(2): 304-318 [DOI: 10.4254/wjh.v14.i2.304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Kizilaslan N, Zekiye Erdem N, Katar M, Gevrek F, Laranjo M. The Effects of Probiotics and Omega-3 Fatty Acids in Liver Steatosis Induced in Rats by High-Fructose Corn Syrup. International Journal of Clinical Practice 2022;2022:1-14. [DOI: 10.1155/2022/7172492] [Reference Citation Analysis]
27 Varani J, Mcclintock SD, Knibbs RN, Harber I, Zeidan D, Jawad-makki MAH, Aslam MN. Liver Protein Expression in Nash Mice on a High-Fat Diet.. [DOI: 10.1101/2022.01.29.478332] [Reference Citation Analysis]
28 Alshawsh MA, Alsalahi A, Alshehade SA, Saghir SAM, Ahmeda AF, Al Zarzour RH, Mahmoud AM. A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet. Molecules 2022;27:858. [PMID: 35164140 DOI: 10.3390/molecules27030858] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
29 Radhakrishnan S, Yeung SF, Ke JY, Antunes MM, Pellizzon MA. Considerations When Choosing High-Fat, High-Fructose, and High-Cholesterol Diets to Induce Experimental Nonalcoholic Fatty Liver Disease in Laboratory Animal Models. Curr Dev Nutr 2021;5:nzab138. [PMID: 34993389 DOI: 10.1093/cdn/nzab138] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Gu CY, Lee TKW. Preclinical mouse models of hepatocellular carcinoma: An overview and update. Experimental Cell Research 2022. [DOI: 10.1016/j.yexcr.2022.113042] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Takahashi Y, Dungubat E, Kusano H, Fukusato T. Histopathological Evaluation of Steatohepatitis in Animal Experiments. Basic Protocols in Foods and Nutrition 2022. [DOI: 10.1007/978-1-0716-2345-9_4] [Reference Citation Analysis]
32 Liu H, Nan B, Yang C, Li X, Yan H, Yuan Y. Elaidic acid induced NLRP3 inflammasome activation via ERS-MAPK signaling pathways in Kupffer cells. Biochim Biophys Acta Mol Cell Biol Lipids 2022;1867:159061. [PMID: 34610469 DOI: 10.1016/j.bbalip.2021.159061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Tursun S, Gülerman HF, Gazyağcı S, Şahin Y, Erel Ö, Neşelioğlu S. Investigation of Thiol/Disulfide Balance in Obese Rats with Non-Alcoholic Fatty Liver Disease. Pediatr Gastroenterol Hepatol Nutr 2021;24:443-54. [PMID: 34557397 DOI: 10.5223/pghn.2021.24.5.443] [Reference Citation Analysis]
34 Jia F, Hu X, Kimura T, Tanaka N. Impact of Dietary Fat on the Progression of Liver Fibrosis: Lessons from Animal and Cell Studies. Int J Mol Sci 2021;22:10303. [PMID: 34638640 DOI: 10.3390/ijms221910303] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
35 Xie Y, Newberry EP, Brunt EM, Ballentine SJ, Soleymanjahi S, Molitor EA, Davidson NO. Inhibition of chylomicron assembly leads to dissociation of hepatic steatosis from inflammation and fibrosis. J Lipid Res 2021;:100123. [PMID: 34563519 DOI: 10.1016/j.jlr.2021.100123] [Reference Citation Analysis]
36 Estévez-Vázquez O, Benedé-Ubieto R, Guo F, Gómez-Santos B, Aspichueta P, Reissing J, Bruns T, Sanz-García C, Sydor S, Bechmann LP, Maranillo E, Sañudo JR, Vázquez MT, Lamas-Paz A, Morán L, Mazariegos MS, Ciudin A, Pericàs JM, Peligros MI, Vaquero J, Martínez-Naves E, Liedtke C, Regueiro JR, Trautwein C, Bañares R, Cubero FJ, Nevzorova YA. Fat: Quality, or Quantity? What Matters Most for the Progression of Metabolic Associated Fatty Liver Disease (MAFLD). Biomedicines 2021;9:1289. [PMID: 34680405 DOI: 10.3390/biomedicines9101289] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Yang B, Wei X, Luo Y, Kan J. Hypoglycemic effect of low-sugar juice derived from Hovenia dulcis on type 1 diabetes mellitus rats. J Sci Food Agric 2021;101:4818-28. [PMID: 33502785 DOI: 10.1002/jsfa.11128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Zaki MYW, Mahdi AK, Patman GL, Whitehead A, Maurício JP, McCain MV, Televantou D, Abou-Beih S, Ramon-Gil E, Watson R, Cox C, Leslie J, Wilson C, Govaere O, Lunec J, Mann DA, Nakjang S, Oakley F, Shukla R, Anstee QM, Tiniakos D, Reeves HL. Key features of the environment promoting liver cancer in the absence of cirrhosis. Sci Rep 2021;11:16727. [PMID: 34408183 DOI: 10.1038/s41598-021-96076-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
39 Sargsyan A, Doridot L, Hannou SA, Tong W, Srinivasan H, Ivison R, Monn R, Kou HH, Haldeman JM, Arlotto M, White PJ, Grimsrud PA, Astapova I, Tsai L, Herman MA. HGFAC is a ChREBP Regulated Hepatokine that Enhances Glucose and Lipid Homeostasis.. [DOI: 10.1101/2021.07.29.454308] [Reference Citation Analysis]
40 Murray JK, Long J, Liu L, Singh S, Pruitt D, Ollmann M, Swearingen E, Hardy M, Homann O, Wu B, Holder JR, Sham K, Herberich B, Lo MC, Dou H, Shkumatov A, Florio M, Rulifson IC. Identification and Optimization of a Minor Allele-Specific Small Interfering RNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease. Nucleic Acid Ther 2021. [PMID: 34297902 DOI: 10.1089/nat.2021.0026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
41 Skat-Rørdam J, Ipsen DH, Hardam PD, Latta M, Lykkesfeldt J, Tveden-Nyborg P. Differential Effects of Dietary Components on Glucose Intolerance and Non-Alcoholic Steatohepatitis. Nutrients 2021;13:2523. [PMID: 34444683 DOI: 10.3390/nu13082523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
42 Basaranoglu M, Kurtoglu A. Replacing the Name of NAFLD With a Metabolic or Another Forename as Indicator of the Era of Stagnation in NASH Studies. J Clin Gastroenterol 2021;55:548-9. [PMID: 33471489 DOI: 10.1097/MCG.0000000000001494] [Reference Citation Analysis]
43 Karkucinska-Wieckowska A, Simoes ICM, Kalinowski P, Lebiedzinska-Arciszewska M, Zieniewicz K, Milkiewicz P, Górska-Ponikowska M, Pinton P, Malik AN, Krawczyk M, Oliveira PJ, Wieckowski MR. Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship. Eur J Clin Invest 2021;:e13622. [PMID: 34050922 DOI: 10.1111/eci.13622] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
44 Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Int J Mol Sci 2021;22:5375. [PMID: 34065331 DOI: 10.3390/ijms22105375] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
45 Hitchen B, Norwood K, Gault VA, Leslie JC. Behavioural evaluation of mouse models of type 2 diabetes. Learning and Motivation 2021;74:101730. [DOI: 10.1016/j.lmot.2021.101730] [Reference Citation Analysis]
46 Okamura T, Hashimoto Y, Majima S, Senmaru T, Ushigome E, Nakanishi N, Asano M, Yamazaki M, Takakuwa H, Hamaguchi M, Fukui M. Trans Fatty Acid Intake Induces Intestinal Inflammation and Impaired Glucose Tolerance. Front Immunol 2021;12:669672. [PMID: 33995404 DOI: 10.3389/fimmu.2021.669672] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
47 Carreres L, Jílková ZM, Vial G, Marche PN, Decaens T, Lerat H. Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review. Biomedicines 2021;9:378. [PMID: 33918467 DOI: 10.3390/biomedicines9040378] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
48 Morikawa R, Nakamoto N, Amiya T, Chu PS, Koda Y, Teratani T, Suzuki T, Kurebayashi Y, Ueno A, Taniki N, Miyamoto K, Yamaguchi A, Shiba S, Katayama T, Yoshida K, Takada Y, Ishihara R, Ebinuma H, Sakamoto M, Kanai T. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis. J Hepatol 2021;74:511-21. [PMID: 33038434 DOI: 10.1016/j.jhep.2020.09.033] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
49 Deguise MO, Pileggi C, De Repentigny Y, Beauvais A, Tierney A, Chehade L, Michaud J, Llavero-Hurtado M, Lamont D, Atrih A, Wishart TM, Gillingwater TH, Schneider BL, Harper ME, Parson SH, Kothary R. SMN Depleted Mice Offer a Robust and Rapid Onset Model of Nonalcoholic Fatty Liver Disease. Cell Mol Gastroenterol Hepatol 2021;12:354-377.e3. [PMID: 33545428 DOI: 10.1016/j.jcmgh.2021.01.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
50 Basaranoglu M. Lean and Nonobese NAFLD/NASH From a Hepatologist's Point of View. J Clin Gastroenterol 2021;55:93-4. [PMID: 32925302 DOI: 10.1097/MCG.0000000000001428] [Reference Citation Analysis]
51 Drapkina O, Kim O, Dadaeva V. The Western diet as payback for civilization: pathophysiological mechanisms and issues for discussion. Profil med 2021;24:94. [DOI: 10.17116/profmed20212405194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Uno K, Miyajima K, Matsumoto M, Toma M, Suzuki-kemuriyama N, Nakae D. Influence of <i>trans</i>-fatty acids on non-alcoholic steatohepatitis with hepatic fibrosis induced by a choline-deficient, methionine-lowered, L-amino acid-defined diet in male Harlan Sprague Dawley rats. Fundam Toxicol Sci 2021;8:221-228. [DOI: 10.2131/fts.8.221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Ravichandra A, Schwabe RF. Mouse Models of Liver Fibrosis. Methods Mol Biol 2021;2299:339-56. [PMID: 34028753 DOI: 10.1007/978-1-0716-1382-5_23] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
54 Ristic-Medic D, Kovacic M, Takic M, Arsic A, Petrovic S, Paunovic M, Jovicic M, Vucic V. Calorie-Restricted Mediterranean and Low-Fat Diets Affect Fatty Acid Status in Individuals with Nonalcoholic Fatty Liver Disease.Nutrients. 2020;13:15. [PMID: 33374554 DOI: 10.3390/nu13010015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
55 Hohenester S, Kanitz V, Schiergens T, Einer C, Nagel J, Wimmer R, Reiter FP, Gerbes AL, De Toni EN, Bauer C, Holdt L, Mayr D, Rust C, Schnurr M, Zischka H, Geier A, Denk G. IL-18 but Not IL-1 Signaling Is Pivotal for the Initiation of Liver Injury in Murine Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E8602. [PMID: 33202693 DOI: 10.3390/ijms21228602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
56 Yang YL, Wang PW, Wang FS, Lin HY, Huang YH. miR-29a Modulates GSK3β/SIRT1-Linked Mitochondrial Proteostatic Stress to Ameliorate Mouse Non-Alcoholic Steatohepatitis. Int J Mol Sci 2020;21:E6884. [PMID: 32961796 DOI: 10.3390/ijms21186884] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
57 Zhang H, Léveillé M, Courty E, Gunes A, N Nguyen B, Estall JL. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease. Am J Physiol Endocrinol Metab 2020;319:E863-76. [PMID: 32924526 DOI: 10.1152/ajpendo.00321.2020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
58 Ramos LF, Silva CM, Pansa CC, Moraes KCM. Non-alcoholic fatty liver disease: molecular and cellular interplays of the lipid metabolism in a steatotic liver. Expert Rev Gastroenterol Hepatol 2021;15:25-40. [PMID: 32892668 DOI: 10.1080/17474124.2020.1820321] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
59 Her Z, Tan JHL, Lim YS, Tan SY, Chan XY, Tan WWS, Liu M, Yong KSM, Lai F, Ceccarello E, Zheng Z, Fan Y, Chang KTE, Sun L, Chang SC, Chin CL, Lee GH, Dan YY, Chan YS, Lim SG, Chan JKY, Chandy KG, Chen Q. CD4+ T Cells Mediate the Development of Liver Fibrosis in High Fat Diet-Induced NAFLD in Humanized Mice. Front Immunol 2020;11:580968. [PMID: 33013934 DOI: 10.3389/fimmu.2020.580968] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
60 Harris SE, Poolman TM, Arvaniti A, Cox RD, Gathercole LL, Tomlinson JW. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2020;319:G345-60. [PMID: 32755310 DOI: 10.1152/ajpgi.00055.2020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
61 Nevzorova YA, Boyer-Diaz Z, Cubero FJ, Gracia-Sancho J. Animal models for liver disease - A practical approach for translational research. J Hepatol 2020;73:423-40. [PMID: 32330604 DOI: 10.1016/j.jhep.2020.04.011] [Cited by in Crossref: 88] [Cited by in F6Publishing: 88] [Article Influence: 29.3] [Reference Citation Analysis]
62 Kim MB, Lee Y, Bae M, Kang H, Pham TX, Hu S, Lee JY, Park YK. Comprehensive characterization of metabolic, inflammatory and fibrotic changes in a mouse model of diet-derived nonalcoholic steatohepatitis. J Nutr Biochem 2020;85:108463. [PMID: 32891893 DOI: 10.1016/j.jnutbio.2020.108463] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
63 Hansen HH, Ægidius HM, Oró D, Evers SS, Heebøll S, Eriksen PL, Thomsen KL, Bengtsson A, Veidal SS, Feigh M, Suppli MP, Knop FK, Grønbæk H, Miranda D, Trevaskis JL, Vrang N, Jelsing J, Rigbolt KTG. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol 2020;20:210. [PMID: 32631250 DOI: 10.1186/s12876-020-01356-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
64 Harada N, Nomura M, Yoda Y, Matsumura S, Inui H, Yamaji R. Food texture affects glucose tolerance by altering pancreatic β-cell function in mice consuming high-fructose corn syrup. PLoS One 2020;15:e0233797. [PMID: 32470042 DOI: 10.1371/journal.pone.0233797] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
65 Xin X, Cai BY, Chen C, Tian HJ, Wang X, Hu YY, Feng Q. High-trans fatty acid and high-sugar diets can cause mice with non-alcoholic steatohepatitis with liver fibrosis and potential pathogenesis. Nutr Metab (Lond) 2020;17:40. [PMID: 32508961 DOI: 10.1186/s12986-020-00462-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
66 Oteng AB, Kersten S. Mechanisms of Action of trans Fatty Acids. Adv Nutr 2020;11:697-708. [PMID: 31782488 DOI: 10.1093/advances/nmz125] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 22.0] [Reference Citation Analysis]
67 Radhakrishnan S, Ke JY, Pellizzon MA. Targeted Nutrient Modifications in Purified Diets Differentially Affect Nonalcoholic Fatty Liver Disease and Metabolic Disease Development in Rodent Models. Curr Dev Nutr 2020;4:nzaa078. [PMID: 32494762 DOI: 10.1093/cdn/nzaa078] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
68 Kakleas K, Christodouli F, Karavanaki K. Nonalcoholic fatty liver disease, insulin resistance, and sweeteners: a literature review. Expert Rev Endocrinol Metab 2020;15:83-93. [PMID: 32212870 DOI: 10.1080/17446651.2020.1740588] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
69 Elshazly SM, Alsemeh AE, Ahmad EAA, Rezq S. CoQ10 exerts hepatoprotective effect in fructose-induced fatty liver model in rats. Pharmacol Rep 2020;72:922-34. [PMID: 32157594 DOI: 10.1007/s43440-020-00075-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Daniels SJ, Leeming DJ, Detlefsen S, Bruun MF, Hjuler ST, Henriksen K, Hein P, Krag A, Karsdal MA, Nielsen MJ, Brockbank S, Cruwys S. Addition of trans fat and alcohol has divergent effects on atherogenic diet-induced liver injury in rodent models of steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2020;318:G410-8. [PMID: 31905026 DOI: 10.1152/ajpgi.00066.2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 Basaranoglu M. Increased prevalence of portal vein thrombosis in patients with nonalcoholic steatohepatitis-cirrhosis due to increased proinflammatory cytokines releasing from abdominal adipose tissue. Eur J Gastroenterol Hepatol 2020;32:458. [PMID: 32011389 DOI: 10.1097/MEG.0000000000001564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
72 Oligschlaeger Y, Shiri-Sverdlov R. NAFLD Preclinical Models: More than a Handful, Less of a Concern? Biomedicines 2020;8:E28. [PMID: 32046285 DOI: 10.3390/biomedicines8020028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
73 Bartolome F, Antequera D, de la Cueva M, Rubio-Fernandez M, Castro N, Pascual C, Camins A, Carro E. Endothelial-specific deficiency of megalin in the brain protects mice against high-fat diet challenge. J Neuroinflammation 2020;17:22. [PMID: 31937343 DOI: 10.1186/s12974-020-1702-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
74 Berná G, Álvarez-amor L, Martín F. Geometry of Nutrition: Nutrients and NAFLD Progression. NAFLD and NASH 2020. [DOI: 10.1007/978-3-030-37173-9_4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 Mundi MS, Velapati S, Patel J, Kellogg TA, Abu Dayyeh BK, Hurt RT. Evolution of NAFLD and Its Management. Nutr Clin Pract 2020;35:72-84. [PMID: 31840865 DOI: 10.1002/ncp.10449] [Cited by in Crossref: 73] [Cited by in F6Publishing: 83] [Article Influence: 18.3] [Reference Citation Analysis]
76 Recena Aydos L, Aparecida do Amaral L, Serafim de Souza R, Jacobowski AC, Freitas Dos Santos E, Rodrigues Macedo ML. Nonalcoholic Fatty Liver Disease Induced by High-Fat Diet in C57bl/6 Models. Nutrients 2019;11:E3067. [PMID: 31888190 DOI: 10.3390/nu11123067] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 11.0] [Reference Citation Analysis]
77 Reimer KC, Wree A, Roderburg C, Tacke F. New drugs for NAFLD: lessons from basic models to the clinic. Hepatol Int 2020;14:8-23. [PMID: 31802390 DOI: 10.1007/s12072-019-10001-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
78 Di Ciaula A, Garruti G, Frühbeck G, De Angelis M, de Bari O, Wang DQ, Lammert F, Portincasa P. The Role of Diet in the Pathogenesis of Cholesterol Gallstones. Curr Med Chem 2019;26:3620-38. [PMID: 28554328 DOI: 10.2174/0929867324666170530080636] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
79 Simoes ICM, Janikiewicz J, Bauer J, Karkucinska-Wieckowska A, Kalinowski P, Dobrzyń A, Wolski A, Pronicki M, Zieniewicz K, Dobrzyń P, Krawczyk M, Zischka H, Wieckowski MR, Potes Y. Fat and Sugar-A Dangerous Duet. A Comparative Review on Metabolic Remodeling in Rodent Models of Nonalcoholic Fatty Liver Disease. Nutrients 2019;11:E2871. [PMID: 31771244 DOI: 10.3390/nu11122871] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
80 Hamdy Gad E, Kamel Y. Introductory Chapter: Nonalcoholic Fatty Liver Disease - What Should We Know? Nonalcoholic Fatty Liver Disease - An Update 2019. [DOI: 10.5772/intechopen.88041] [Reference Citation Analysis]
81 Galassi TV, Jena PV, Shah J, Ao G, Molitor E, Bram Y, Frankel A, Park J, Jessurun J, Ory DS, Haimovitz-Friedman A, Roxbury D, Mittal J, Zheng M, Schwartz RE, Heller DA. An optical nanoreporter of endolysosomal lipid accumulation reveals enduring effects of diet on hepatic macrophages in vivo. Sci Transl Med. 2018;10. [PMID: 30282694 DOI: 10.1126/scitranslmed.aar2680] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 15.5] [Reference Citation Analysis]
82 Boland ML, Oró D, Tølbøl KS, Thrane ST, Nielsen JC, Cohen TS, Tabor DE, Fernandes F, Tovchigrechko A, Veidal SS, Warrener P, Sellman BR, Jelsing J, Feigh M, Vrang N, Trevaskis JL, Hansen HH. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source. World J Gastroenterol 2019; 25(33): 4904-4920 [PMID: 31543682 DOI: 10.3748/wjg.v25.i33.4904] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 51] [Article Influence: 12.8] [Reference Citation Analysis]
83 Baldini F, Bartolozzi A, Ardito M, Voci A, Portincasa P, Vassalli M, Vergani L. Biomechanics of cultured hepatic cells during different steatogenic hits. Journal of the Mechanical Behavior of Biomedical Materials 2019;97:296-305. [DOI: 10.1016/j.jmbbm.2019.05.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
84 Han L, Bittner S, Dong D, Cortez Y, Dulay H, Arshad S, Shen WJ, Kraemer FB, Azhar S. Creosote bush-derived NDGA attenuates molecular and pathological changes in a novel mouse model of non-alcoholic steatohepatitis (NASH). Mol Cell Endocrinol 2019;498:110538. [PMID: 31415794 DOI: 10.1016/j.mce.2019.110538] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
85 Oteng AB, Loregger A, van Weeghel M, Zelcer N, Kersten S. Industrial Trans Fatty Acids Stimulate SREBP2-Mediated Cholesterogenesis and Promote Non-Alcoholic Fatty Liver Disease. Mol Nutr Food Res 2019;63:e1900385. [PMID: 31327168 DOI: 10.1002/mnfr.201900385] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
86 Parikh ND, Marrero WJ, Wang J, Steuer J, Tapper EB, Konerman M, Singal AG, Hutton DW, Byon E, Lavieri MS. Projected increase in obesity and non-alcoholic-steatohepatitis-related liver transplantation waitlist additions in the United States. Hepatology 2019;70:487-95. [PMID: 28833326 DOI: 10.1002/hep.29473] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 15.8] [Reference Citation Analysis]
87 Savari F, Mard SA, Badavi M, Rezaie A, Gharib-Naseri MK. A new method to induce nonalcoholic steatohepatitis (NASH) in mice. BMC Gastroenterol 2019;19:125. [PMID: 31307427 DOI: 10.1186/s12876-019-1041-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
88 Perdomo CM, Frühbeck G, Escalada J. Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease. Nutrients 2019;11:E677. [PMID: 30901929 DOI: 10.3390/nu11030677] [Cited by in Crossref: 79] [Cited by in F6Publishing: 89] [Article Influence: 19.8] [Reference Citation Analysis]
89 Sun G, Jackson CV, Zimmerman K, Zhang LK, Finnearty CM, Sandusky GE, Zhang G, Peterson RG, Wang YJ. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose. BMC Gastroenterol 2019;19:41. [PMID: 30885145 DOI: 10.1186/s12876-019-0958-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
90 Clark WA, Cress EM. Nutritional Issues and Positive Living in Human Immunodeficiency Virus/AIDS. Nurs Clin North Am 2018;53:13-24. [PMID: 29362057 DOI: 10.1016/j.cnur.2017.10.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
91 Finck BN. Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis. Diabetes 2018;67:2485-93. [PMID: 30459251 DOI: 10.2337/dbi18-0024] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 15.3] [Reference Citation Analysis]
92 Puri BK, Kingston MC, Monro JA. Fructose-associated hepatotoxicity indexed by the lactate dehydrogenase isoenzyme LDH-5. Med Hypotheses 2019;124:40-1. [PMID: 30798914 DOI: 10.1016/j.mehy.2019.02.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
93 Longhi R. Trans fatty acid in the liver and central nervous system. Dietary Interventions in Liver Disease 2019. [DOI: 10.1016/b978-0-12-814466-4.00023-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Cai CX, Carlos S, Solaimani P, Trivedi BJ, Tran C, Castelino-prabhu S. Nutritional and Dietary Interventions for Nonalcoholic Fatty Liver Disease. Dietary Interventions in Liver Disease 2019. [DOI: 10.1016/b978-0-12-814466-4.00029-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
95 Einer C, Leitzinger C, Lichtmannegger J, Eberhagen C, Rieder T, Borchard S, Wimmer R, Denk G, Popper B, Neff F, Polishchuk EV, Polishchuk RS, Hauck SM, von Toerne C, Müller JC, Karst U, Baral BS, DiSpirito AA, Kremer AE, Semrau J, Weiss KH, Hohenester S, Zischka H. A High-Calorie Diet Aggravates Mitochondrial Dysfunction and Triggers Severe Liver Damage in Wilson Disease Rats. Cell Mol Gastroenterol Hepatol 2019;7:571-96. [PMID: 30586623 DOI: 10.1016/j.jcmgh.2018.12.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
96 Rojas JM, Bolze F, Thorup I, Nowak J, Dalsgaard CM, Skydsgaard M, Berthelsen LO, Keane KA, Søeborg H, Sjögren I, Jensen JT, Fels JJ, Offenberg HK, Andersen LW, Dalgaard M. The Effect of Diet-induced Obesity on Toxicological Parameters in the Polygenic Sprague-Dawley Rat Model. Toxicol Pathol 2018;46:777-98. [DOI: 10.1177/0192623318803557] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
97 Turchinovich A, Baranova A, Drapkina O, Tonevitsky A. Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders. Front Physiol 2018;9:1256. [PMID: 30294278 DOI: 10.3389/fphys.2018.01256] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
98 Li R, Li J, Huang Y, Li H, Yan S, Lin J, Chen Y, Wu L, Liu B, Wang G, Lan T. Polydatin attenuates diet-induced nonalcoholic steatohepatitis and fibrosis in mice. Int J Biol Sci 2018;14:1411-25. [PMID: 30262993 DOI: 10.7150/ijbs.26086] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
99 Jahn D, Kircher S, Hermanns HM, Geier A. Animal models of NAFLD from a hepatologist's point of view. Biochim Biophys Acta Mol Basis Dis 2019;1865:943-53. [PMID: 29990551 DOI: 10.1016/j.bbadis.2018.06.023] [Cited by in Crossref: 68] [Cited by in F6Publishing: 75] [Article Influence: 13.6] [Reference Citation Analysis]
100 Dalvi PS, Yang S, Swain N, Kim J, Saha S, Bourdon C, Zhang L, Chami R, Bandsma RHJ. Long-term metabolic effects of malnutrition: Liver steatosis and insulin resistance following early-life protein restriction. PLoS One 2018;13:e0199916. [PMID: 29965973 DOI: 10.1371/journal.pone.0199916] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
101 Kisioglu B, Nergiz-Unal R. Potential effect of maternal dietary sucrose or fructose syrup on CD36, leptin, and ghrelin-mediated fetal programming of obesity. Nutr Neurosci 2020;23:210-20. [PMID: 29961406 DOI: 10.1080/1028415X.2018.1491151] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
102 Hardy T, Day CP. Non-Alcoholic Fatty Liver Disease. Sherlock's Diseases of the Liver and Biliary System 2018. [DOI: 10.1002/9781119237662.ch28] [Reference Citation Analysis]
103 Marinho PC, Vieira AB, Pereira PG, Rabelo K, Ciambarella BT, Nascimento ALR, Cortez E, Moura AS, Guimarães FV, Martins MA, Barquero G, Ferreira RN, de Carvalho JJ. Capybara Oil Improves Hepatic Mitochondrial Dysfunction, Steatosis, and Inflammation in a Murine Model of Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med 2018;2018:4956079. [PMID: 29853957 DOI: 10.1155/2018/4956079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
104 Mahady SE, Adams LA. Burden of non-alcoholic fatty liver disease in Australia. J Gastroenterol Hepatol 2018;33 Suppl 1:1-11. [PMID: 29851153 DOI: 10.1111/jgh.14270] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
105 Klaunig JE, Li X, Wang Z. Role of xenobiotics in the induction and progression of fatty liver disease. Toxicol Res (Camb) 2018;7:664-80. [PMID: 30090613 DOI: 10.1039/c7tx00326a] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
106 Canter RJ, Le CT, Beerthuijzen JMT, Murphy WJ. Obesity as an immune-modifying factor in cancer immunotherapy. J Leukoc Biol 2018;104:487-97. [PMID: 29762866 DOI: 10.1002/JLB.5RI1017-401RR] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
107 Denk H, Abuja PM, Zatloukal K. Animal models of NAFLD from the pathologist's point of view. Biochim Biophys Acta Mol Basis Dis. 2019;1865:929-942. [PMID: 29746920 DOI: 10.1016/j.bbadis.2018.04.024] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
108 Liu X, Peng Y, Chen S, Sun Q. An observational study on the association between major dietary patterns and non-alcoholic fatty liver disease in Chinese adolescents. Medicine (Baltimore) 2018;97:e0576. [PMID: 29703050 DOI: 10.1097/MD.0000000000010576] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
109 Bertola A. WITHDRAWN: Rodent models of fatty liver diseases. Liver Research 2018. [DOI: 10.1016/j.livres.2018.02.005] [Reference Citation Analysis]
110 Kim MY. [The Progression of Liver Fibrosis in Non-alcoholic Fatty Liver Disease]. Korean J Gastroenterol 2017;69:341-7. [PMID: 28637102 DOI: 10.4166/kjg.2017.69.6.341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
111 Hwang JT, Shin EJ, Chung MY, Park JH, Chung S, Choi HK. Ethanol extract of Allium fistulosum inhibits development of non-alcoholic fatty liver disease. Nutr Res Pract 2018;12:110-7. [PMID: 29629027 DOI: 10.4162/nrp.2018.12.2.110] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
112 Parkash O, Saeed S. Molecular Basis for Pathogenesis of Steatohepatitis: Contemporary Understanding and New Insights. Non-Alcoholic Fatty Liver Disease - Molecular Bases, Prevention and Treatment 2018. [DOI: 10.5772/intechopen.71405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
113 Bertola A. Rodent models of fatty liver diseases. Liver Research 2018;2:3-13. [DOI: 10.1016/j.livres.2018.03.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
114 Chan JKW, Bittner S, Bittner A, Atwal S, Shen WJ, Inayathullah M, Rajada J, Nicolls MR, Kraemer FB, Azhar S. Nordihydroguaiaretic Acid, a Lignan from Larrea tridentata (Creosote Bush), Protects Against American Lifestyle-Induced Obesity Syndrome Diet-Induced Metabolic Dysfunction in Mice. J Pharmacol Exp Ther 2018;365:281-90. [PMID: 29472517 DOI: 10.1124/jpet.117.243733] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
115 Hung CK, Bodenheimer HC Jr. Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clin Liver Dis 2018;22:175-87. [PMID: 29128055 DOI: 10.1016/j.cld.2017.08.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
116 Wu J. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Oncotarget 2016;7:42762-76. [PMID: 27072576 DOI: 10.18632/oncotarget.8641] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
117 Tølbøl KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, Jelsing J, Vrang N, Feigh M. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol 2018; 24(2): 179-194 [PMID: 29375204 DOI: 10.3748/wjg.v24.i2.179] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 78] [Article Influence: 15.4] [Reference Citation Analysis]
118 Roth JD, Feigh M, Veidal SS, Fensholdt LK, Rigbolt KT, Hansen HH, Chen LC, Petitjean M, Friley W, Vrang N, Jelsing J, Young M. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis. World J Gastroenterol 2018; 24(2): 195-210 [PMID: 29375205 DOI: 10.3748/wjg.v24.i2.195] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 42] [Article Influence: 8.6] [Reference Citation Analysis]
119 Oseini AM, Cole BK, Issa D, Feaver RE, Sanyal AJ. Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis. Hepatol Int 2018;12:6-16. [PMID: 29299759 DOI: 10.1007/s12072-017-9838-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
120 Farrell GC, Haczeyni F, Chitturi S. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease. Adv Exp Med Biol 2018;1061:19-44. [PMID: 29956204 DOI: 10.1007/978-981-10-8684-7_3] [Cited by in Crossref: 82] [Cited by in F6Publishing: 86] [Article Influence: 16.4] [Reference Citation Analysis]
121 Edmunds LR, Otero PA, Sharma L, D'Souza S, Dolezal JM, David S, Lu J, Lamm L, Basantani M, Zhang P, Sipula IJ, Li L, Zeng X, Ding Y, Ding F, Beck ME, Vockley J, Monga SP, Kershaw EE, O'Doherty RM, Kratz LE, Yates NA, Goetzman EP, Scott D, Duncan AW, Prochownik EV. Abnormal lipid processing but normal long-term repopulation potential of myc-/- hepatocytes. Oncotarget 2016;7:30379-95. [PMID: 27105497 DOI: 10.18632/oncotarget.8856] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
122 Okano K, Shitamoto K, Araki M, Kawamoto C, Kawano R, Nogaki H. Influencing factors in quantitative measurement using activated platelet levels and platelet-activating capacity for the assessment of thrombosis in pre-metabolic syndrome and type 2 diabetes mellitus. Nurs Health Sci 2018;20:69-78. [PMID: 29235231 DOI: 10.1111/nhs.12389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
123 Rao A, Kosters A, Mells JE, Zhang W, Setchell KD, Amanso AM, Wynn GM, Xu T, Keller BT, Yin H, Banton S, Jones DP, Wu H, Dawson PA, Karpen SJ. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice. Sci Transl Med 2016;8:357ra122. [PMID: 27655848 DOI: 10.1126/scitranslmed.aaf4823] [Cited by in Crossref: 118] [Cited by in F6Publishing: 123] [Article Influence: 19.7] [Reference Citation Analysis]
124 Cole BK, Feaver RE, Wamhoff BR, Dash A. Non-alcoholic fatty liver disease (NAFLD) models in drug discovery. Expert Opin Drug Discov 2018;13:193-205. [PMID: 29190166 DOI: 10.1080/17460441.2018.1410135] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
125 Danford CJ, Sanchez JE, Corey KE. Managing the Burden of Non-NASH NAFLD. Curr Hepatol Rep 2017;16:326-34. [PMID: 29503789 DOI: 10.1007/s11901-017-0371-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
126 Argo CK, Henry ZH, Caldwell SH. Nonalcoholic Fatty Liver Disease. Schiff's Diseases of the Liver 2017. [DOI: 10.1002/9781119251316.ch32] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
127 Khadge S, Sharp JG, Thiele GM, McGuire TR, Klassen LW, Duryee MJ, Britton HC, Dafferner AJ, Beck J, Black PN, DiRusso CC, Talmadge J. Dietary omega-3 and omega-6 polyunsaturated fatty acids modulate hepatic pathology. J Nutr Biochem 2018;52:92-102. [PMID: 29175671 DOI: 10.1016/j.jnutbio.2017.09.017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
128 Van Herck MA, Vonghia L, Francque SM. Animal Models of Nonalcoholic Fatty Liver Disease-A Starter's Guide. Nutrients. 2017;9:1072. [PMID: 28953222 DOI: 10.3390/nu9101072] [Cited by in Crossref: 170] [Cited by in F6Publishing: 182] [Article Influence: 28.3] [Reference Citation Analysis]
129 Einer C, Hohenester S, Wimmer R, Wottke L, Artmann R, Schulz S, Gosmann C, Simmons A, Leitzinger C, Eberhagen C, Borchard S, Schmitt S, Hauck SM, von Toerne C, Jastroch M, Walheim E, Rust C, Gerbes AL, Popper B, Mayr D, Schnurr M, Vollmar AM, Denk G, Zischka H. Mitochondrial adaptation in steatotic mice. Mitochondrion 2018;40:1-12. [PMID: 28935446 DOI: 10.1016/j.mito.2017.08.015] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 6.5] [Reference Citation Analysis]
130 Einer C, Hohenester S, Wimmer R, Wottke L, Artmann R, Schulz S, Gosmann C, Simmons A, Leitzinger C, Eberhagen C, Borchard S, Schmitt S, Hauck SM, von Toerne C, Jastroch M, Walheim E, Rust C, Gerbes AL, Popper B, Mayr D, Schnurr M, Vollmar AM, Denk G, Zischka H. Data on chow, liver tissue and mitochondrial fatty acid compositions as well as mitochondrial proteome changes after feeding mice a western diet for 6-24 weeks. Data Brief 2017;15:163-9. [PMID: 29034285 DOI: 10.1016/j.dib.2017.09.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
131 Rajamoorthi A, Arias N, Basta J, Lee RG, Baldán Á. Amelioration of diet-induced steatohepatitis in mice following combined therapy with ASO-Fsp27 and fenofibrate. J Lipid Res 2017;58:2127-38. [PMID: 28874443 DOI: 10.1194/jlr.M077941] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
132 Samala N, Tersey SA, Chalasani N, Anderson RM, Mirmira RG. Molecular mechanisms of nonalcoholic fatty liver disease: Potential role for 12-lipoxygenase. J Diabetes Complications 2017;31:1630-7. [PMID: 28886991 DOI: 10.1016/j.jdiacomp.2017.07.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
133 Jeyapal S, Putcha UK, Mullapudi VS, Ghosh S, Sakamuri A, Kona SR, Vadakattu SS, Madakasira C, Ibrahim A. Chronic consumption of fructose in combination with trans fatty acids but not with saturated fatty acids induces nonalcoholic steatohepatitis with fibrosis in rats. Eur J Nutr. 2018;57:2171-2187. [PMID: 28676973 DOI: 10.1007/s00394-017-1492-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
134 Hansen HH, Feigh M, Veidal SS, Rigbolt KT, Vrang N, Fosgerau K. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discov Today. 2017;22:1707-1718. [PMID: 28687459 DOI: 10.1016/j.drudis.2017.06.007] [Cited by in Crossref: 126] [Cited by in F6Publishing: 107] [Article Influence: 21.0] [Reference Citation Analysis]
135 Tessitore A, Mastroiaco V, Vetuschi A, Sferra R, Pompili S, Cicciarelli G, Barnabei R, Capece D, Zazzeroni F, Capalbo C, Alesse E. Development of hepatocellular cancer induced by long term low fat-high carbohydrate diet in a NAFLD/NASH mouse model. Oncotarget 2017;8:53482-94. [PMID: 28881825 DOI: 10.18632/oncotarget.18585] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
136 Abdussalam A, Elshenawy OH, bin Jardan YA, El-kadi AO, Brocks DR. The Obesogenic Potency of Various High-Caloric Diet Compositions in Male Rats, and Their Effects on Expression of Liver and Kidney Proteins Involved in Drug Elimination. Journal of Pharmaceutical Sciences 2017;106:1650-8. [DOI: 10.1016/j.xphs.2017.02.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
137 Heier EC, Meier A, Julich-Haertel H, Djudjaj S, Rau M, Tschernig T, Geier A, Boor P, Lammert F, Lukacs-Kornek V. Murine CD103(+) dendritic cells protect against steatosis progression towards steatohepatitis. J Hepatol 2017;66:1241-50. [PMID: 28108233 DOI: 10.1016/j.jhep.2017.01.008] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
138 Duwaerts CC, Amin AM, Siao K, Her C, Fitch M, Beysen C, Turner SM, Goodsell A, Baron JL, Grenert JP, Cho SJ, Maher JJ. Specific Macronutrients Exert Unique Influences on the Adipose-Liver Axis to Promote Hepatic Steatosis in Mice. Cell Mol Gastroenterol Hepatol 2017;4:223-36. [PMID: 28649594 DOI: 10.1016/j.jcmgh.2017.04.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
139 Dietrich CG, Rau M, Jahn D, Geier A. Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease. Expert Opin Drug Metab Toxicol 2017;13:625-40. [PMID: 28359183 DOI: 10.1080/17425255.2017.1314461] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
140 Cioffi F, Senese R, Lasala P, Ziello A, Mazzoli A, Crescenzo R, Liverini G, Lanni A, Goglia F, Iossa S. Fructose-Rich Diet Affects Mitochondrial DNA Damage and Repair in Rats. Nutrients 2017;9:E323. [PMID: 28338610 DOI: 10.3390/nu9040323] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 7.8] [Reference Citation Analysis]
141 Mokhtari Z, Gibson DL, Hekmatdoost A. Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. Adv Nutr 2017;8:240-52. [PMID: 28298269 DOI: 10.3945/an.116.013151] [Cited by in Crossref: 94] [Cited by in F6Publishing: 100] [Article Influence: 15.7] [Reference Citation Analysis]
142 Hsu CC, Ness E, Kowdley KV. Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease. Adv Nutr. 2017;8:253-265. [PMID: 28298270 DOI: 10.3945/an.116.013730] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
143 Amano Y, Shimizu F, Yasuno H, Harada A, Tsuchiya S, Isono O, Nagabukuro H, Tozawa R. Non-alcoholic steatohepatitis-associated hepatic fibrosis and hepatocellular carcinoma in a combined mouse model of genetic modification and dietary challenge. Hepatol Res 2017;47:103-15. [PMID: 26992446 DOI: 10.1111/hepr.12709] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
144 Takahashi Y, Fukusato T. Animal Models of Liver Diseases. Animal Models for the Study of Human Disease 2017. [DOI: 10.1016/b978-0-12-809468-6.00013-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
145 Tan H, Chang JP. Non-Alcoholic Fatty Liver Disease. Proceedings of Singapore Healthcare 2010;19:36-50. [DOI: 10.1177/201010581001900106] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
146 Cabrera D, Ruiz A, Cabello-Verrugio C, Brandan E, Estrada L, Pizarro M, Solis N, Torres J, Barrera F, Arrese M. Diet-Induced Nonalcoholic Fatty Liver Disease Is Associated with Sarcopenia and Decreased Serum Insulin-Like Growth Factor-1. Dig Dis Sci 2016;61:3190-8. [PMID: 27572941 DOI: 10.1007/s10620-016-4285-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
147 Rahman K, Desai C, Iyer SS, Thorn NE, Kumar P, Liu Y, Smith T, Neish AS, Li H, Tan S, Wu P, Liu X, Yu Y, Farris AB, Nusrat A, Parkos CA, Anania FA. Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol. Gastroenterology 2016;151:733-746.e12. [PMID: 27342212 DOI: 10.1053/j.gastro.2016.06.022] [Cited by in Crossref: 177] [Cited by in F6Publishing: 181] [Article Influence: 25.3] [Reference Citation Analysis]
148 Mahady SE, George J. Exercise and diet in the management of nonalcoholic fatty liver disease. Metabolism 2016;65:1172-82. [DOI: 10.1016/j.metabol.2015.10.032] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 5.6] [Reference Citation Analysis]
149 Larner DP, Morgan SA, Gathercole LL, Doig CL, Guest P, Weston C, Hazeldine J, Tomlinson JW, Stewart PM, Lavery GG. Male 11β-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease. Endocrinology 2016;157:3493-504. [PMID: 27384305 DOI: 10.1210/en.2016-1357] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
150 Kristiansen MNB, Veidal SS, Rigbolt KTG, Tølbøl KS, Roth JD, Jelsing J, Vrang N, Feigh M. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy. World J Hepatol 2016; 8(16): 673-684 [PMID: 27326314 DOI: 10.4254/wjh.v8.i16.673] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 12.0] [Reference Citation Analysis]
151 Rahman K, Liu Y, Kumar P, Smith T, Thorn NE, Farris AB, Anania FA. C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis. Lab Invest 2016;96:895-908. [PMID: 27239734 DOI: 10.1038/labinvest.2016.61] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
152 Boyraz M, Pirgon Ö, Dündar B, Çekmez F, Hatipoğlu N. Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease. J Clin Res Pediatr Endocrinol 2015;7:121-7. [PMID: 26316434 DOI: 10.4274/jcrpe.1749] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
153 Lin J, Chen A. Perilipin 5 restores the formation of lipid droplets in activated hepatic stellate cells and inhibits their activation. Lab Invest 2016;96:791-806. [PMID: 27135793 DOI: 10.1038/labinvest.2016.53] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
154 Ibrahim SH, Hirsova P, Malhi H, Gores GJ. Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame. Dig Dis Sci 2016;61:1325-36. [PMID: 26626909 DOI: 10.1007/s10620-015-3977-1] [Cited by in Crossref: 138] [Cited by in F6Publishing: 135] [Article Influence: 19.7] [Reference Citation Analysis]
155 Kanwar P, Kowdley KV. The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. Clin Liver Dis 2016;20:225-43. [PMID: 27063266 DOI: 10.1016/j.cld.2015.10.002] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 9.7] [Reference Citation Analysis]
156 Basaranoglu M, Najjar SM, Demirbag AE, Senturk H. Significant cohort of non-alcoholic fatty liver disease with portal vein thrombosis in transplant waiting list. World J Hepatol 2016; 8(7): 376-384 [PMID: 26981175 DOI: 10.4254/wjh.v8.i7.376] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
157 Jarukamjorn K, Jearapong N, Pimson C, Chatuphonprasert W. A High-Fat, High-Fructose Diet Induces Antioxidant Imbalance and Increases the Risk and Progression of Nonalcoholic Fatty Liver Disease in Mice. Scientifica (Cairo) 2016;2016:5029414. [PMID: 27019761 DOI: 10.1155/2016/5029414] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
158 Gleeson MW, Dickson RC. Quelling Inflammation with Ketosis and Steric Chemistry. Clin Transl Gastroenterol 2016;7:e145. [PMID: 26890268 DOI: 10.1038/ctg.2016.6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
159 Qureshi K, Abrams GA. Prevalence of biopsy-proven non-alcoholic fatty liver disease in severely obese subjects without metabolic syndrome. Clin Obes 2016;6:117-23. [PMID: 26856683 DOI: 10.1111/cob.12132] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
160 Stacchiotti A, Favero G, Lavazza A, Golic I, Aleksic M, Korac A, Rodella LF, Rezzani R. Hepatic Macrosteatosis Is Partially Converted to Microsteatosis by Melatonin Supplementation in ob/ob Mice Non-Alcoholic Fatty Liver Disease. PLoS One 2016;11:e0148115. [PMID: 26824477 DOI: 10.1371/journal.pone.0148115] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
161 Honda Y, Imajo K, Kato T, Kessoku T, Ogawa Y, Tomeno W, Kato S, Mawatari H, Fujita K, Yoneda M, Saito S, Nakajima A. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. PLoS One. 2016;11:e0146337. [PMID: 26731267 DOI: 10.1371/journal.pone.0146337] [Cited by in Crossref: 112] [Cited by in F6Publishing: 117] [Article Influence: 16.0] [Reference Citation Analysis]
162 Ferrere G, Leroux A, Wrzosek L, Puchois V, Gaudin F, Ciocan D, Renoud ML, Naveau S, Perlemuter G, Cassard AM. Activation of Kupffer Cells Is Associated with a Specific Dysbiosis Induced by Fructose or High Fat Diet in Mice. PLoS One 2016;11:e0146177. [PMID: 26731543 DOI: 10.1371/journal.pone.0146177] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
163 Smolle E, Kessler SM, Golob N, Haybaeck J. Nonalcoholic Fatty Liver Disease. Metabolic Syndrome 2016. [DOI: 10.1007/978-3-319-11251-0_36] [Reference Citation Analysis]
164 Maher JJ. Pathogenesis of NAFLD and NASH. In: Chalasani N, Szabo G, editors. Alcoholic and Non-Alcoholic Fatty Liver Disease. Cham: Springer International Publishing; 2016. pp. 71-101. [DOI: 10.1007/978-3-319-20538-0_4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
165 Luo Y, Burrington CM, Graff EC, Zhang J, Judd RL, Suksaranjit P, Kaewpoowat Q, Davenport SK, O'Neill AM, Greene MW. Metabolic phenotype and adipose and liver features in a high-fat Western diet-induced mouse model of obesity-linked NAFLD. Am J Physiol Endocrinol Metab 2016;310:E418-39. [PMID: 26670487 DOI: 10.1152/ajpendo.00319.2015] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 6.1] [Reference Citation Analysis]
166 Liu X, Henkel AS, LeCuyer BE, Schipma MJ, Anderson KA, Green RM. Hepatocyte X-box binding protein 1 deficiency increases liver injury in mice fed a high-fat/sugar diet. Am J Physiol Gastrointest Liver Physiol 2015;309:G965-74. [PMID: 26472223 DOI: 10.1152/ajpgi.00132.2015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
167 Pierce AA, Duwaerts CC, Soon RK, Siao K, Grenert JP, Fitch M, Hellerstein MK, Beysen C, Turner SM, Maher JJ. Isocaloric manipulation of macronutrients within a high-carbohydrate/moderate-fat diet induces unique effects on hepatic lipogenesis, steatosis and liver injury. J Nutr Biochem 2016;29:12-20. [PMID: 26895660 DOI: 10.1016/j.jnutbio.2015.10.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
168 Jump DB, Depner CM, Tripathy S, Lytle KA. Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer. Adv Nutr 2015;6:694-702. [PMID: 26567194 DOI: 10.3945/an.115.009423] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 5.9] [Reference Citation Analysis]
169 Reid DT, Eksteen B. Murine models provide insight to the development of non-alcoholic fatty liver disease. Nutr Res Rev. 2015;28:133-142. [PMID: 26494024 DOI: 10.1017/s0954422415000128] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
170 Abu-Serie MM, El-Gamal BA, El-Kersh MA, El-Saadani MA. Investigation into the antioxidant role of arginine in the treatment and the protection for intralipid-induced non-alcoholic steatohepatitis. Lipids Health Dis 2015;14:128. [PMID: 26463841 DOI: 10.1186/s12944-015-0124-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
171 Pavlides M, Cobbold JF. Non-alcoholic fatty liver disease. Medicine 2015;43:585-589. [DOI: 10.1016/j.mpmed.2015.07.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
172 Chaix A, Zarrinpar A, Miu P, Panda S. Time-restricted feeding is a preventative and therapeutic intervention against diverse nutritional challenges. Cell Metab 2014;20:991-1005. [PMID: 25470547 DOI: 10.1016/j.cmet.2014.11.001] [Cited by in Crossref: 516] [Cited by in F6Publishing: 452] [Article Influence: 64.5] [Reference Citation Analysis]
173 Ruiz-Ramírez A, Barrios-Maya MA, López-Acosta O, Molina-Ortiz D, El-Hafidi M. Cytochrome c release from rat liver mitochondria is compromised by increased saturated cardiolipin species induced by sucrose feeding. Am J Physiol Endocrinol Metab 2015;309:E777-86. [PMID: 26353385 DOI: 10.1152/ajpendo.00617.2014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
174 Jearapong N, Chatuphonprasert W, Jarukamjorn K. Effect of tetrahydrocurcumin on the profiles of drug-metabolizing enzymes induced by a high fat and high fructose diet in mice. Chemico-Biological Interactions 2015;239:67-75. [DOI: 10.1016/j.cbi.2015.06.022] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
175 Jump DB, Depner CM, Tripathy S, Lytle KA. Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr-/- mice. Proc Nutr Soc 2016;75:1-9. [PMID: 26282529 DOI: 10.1017/S002966511500244X] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
176 Hamza N, Berke B, Cheze C, Marais S, Lorrain S, Abdouelfath A, Lassalle R, Carles D, Gin H, Moore N. Effect of Centaurium erythraea Rafn, Artemisia herba-alba Asso and Trigonella foenum-graecum L. on liver fat accumulation in C57BL/6J mice with high-fat diet-induced type 2 diabetes. Journal of Ethnopharmacology 2015;171:4-11. [DOI: 10.1016/j.jep.2015.05.027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
177 Fakhoury-Sayegh N, Trak-Smayra V, Khazzaka A, Esseily F, Obeid O, Lahoud-Zouein M, Younes H. Characteristics of nonalcoholic fatty liver disease induced in wistar rats following four different diets. Nutr Res Pract 2015;9:350-7. [PMID: 26244072 DOI: 10.4162/nrp.2015.9.4.350] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
178 Ganz M, Bukong TN, Csak T, Saha B, Park JK, Ambade A, Kodys K, Szabo G. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice. J Transl Med 2015;13:193. [PMID: 26077675 DOI: 10.1186/s12967-015-0552-7] [Cited by in Crossref: 81] [Cited by in F6Publishing: 82] [Article Influence: 10.1] [Reference Citation Analysis]
179 Basaranoglu M, Basaranoglu G, Bugianesi E. Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. Hepatobiliary Surg Nutr 2015;4:109-16. [PMID: 26005677 DOI: 10.3978/j.issn.2304-3881.2014.11.05] [Cited by in F6Publishing: 74] [Reference Citation Analysis]
180 Lee JS, Jun DW, Kim EK, Jeon HJ, Nam HH, Saeed WK. Histologic and Metabolic Derangement in High-Fat, High-Fructose, and Combination Diet Animal Models. ScientificWorldJournal 2015;2015:306326. [PMID: 26090514 DOI: 10.1155/2015/306326] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
181 Zhao L, Zhong S, Qu H, Xie Y, Cao Z, Li Q, Yang P, Varghese Z, Moorhead JF, Chen Y, Ruan XZ. Chronic inflammation aggravates metabolic disorders of hepatic fatty acids in high-fat diet-induced obese mice. Sci Rep 2015;5:10222. [PMID: 25974206 DOI: 10.1038/srep10222] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
182 Sanches SC, Ramalho LN, Augusto MJ, da Silva DM, Ramalho FS. Nonalcoholic Steatohepatitis: A Search for Factual Animal Models. Biomed Res Int. 2015;2015:574832. [PMID: 26064924 DOI: 10.1155/2015/574832] [Cited by in Crossref: 115] [Cited by in F6Publishing: 124] [Article Influence: 14.4] [Reference Citation Analysis]
183 Basaranoglu M, Canbakan B, Yildiz K, Ceylan B, Baysal B, Uysal O, Senturk H. Nonalcoholic fatty liver may increase the risk of operation in patients with fatty liver and the frequency of cancer in their first-degree relatives. Wien Klin Wochenschr 2016;128:691-4. [PMID: 25869759 DOI: 10.1007/s00508-015-0744-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
184 Wauquier F, Léotoing L, Philippe C, Spilmont M, Coxam V, Wittrant Y. Pros and cons of fatty acids in bone biology. Prog Lipid Res 2015;58:121-45. [PMID: 25835096 DOI: 10.1016/j.plipres.2015.03.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
185 Delire B, Stärkel P, Leclercq I. Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development. J Clin Transl Hepatol 2015;3:53-66. [PMID: 26357635 DOI: 10.14218/JCTH.2014.00035] [Cited by in Crossref: 98] [Cited by in F6Publishing: 98] [Article Influence: 12.3] [Reference Citation Analysis]
186 Barreyro FJ, Holod S, Finocchietto PV, Camino AM, Aquino JB, Avagnina A, Carreras MC, Poderoso JJ, Gores GJ. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int 2015;35:953-66. [PMID: 24750664 DOI: 10.1111/liv.12570] [Cited by in Crossref: 199] [Cited by in F6Publishing: 189] [Article Influence: 24.9] [Reference Citation Analysis]
187 Kanuri G, Ladurner R, Skibovskaya J, Spruss A, Königsrainer A, Bischoff SC, Bergheim I. Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease. Liver Int 2015;35:562-8. [PMID: 24351080 DOI: 10.1111/liv.12442] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
188 Jia X, Naito H, Kitamori K, Yetti H, Nakajima T. The Progression of Non-alcoholic Fatty Liver Disease and Lifestyle Intervention in Older Adults. Foods and Dietary Supplements in the Prevention and Treatment of Disease in Older Adults 2015. [DOI: 10.1016/b978-0-12-418680-4.00009-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
189 Smolle E, Kessler SM, Golob N, Haybaeck J. Non-alcoholic Fatty Liver Disease. Metabolic Syndrome 2015. [DOI: 10.1007/978-3-319-12125-3_36-1] [Reference Citation Analysis]
190 Sharma D, Saxena NK. Mouse Models to Study the Effect of Natural Products on Obesity-Associated NAFLD/NASH. Energy Balance and Cancer 2015. [DOI: 10.1007/978-3-319-16733-6_12] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
191 Weston CJ, Shepherd EL, Claridge LC, Rantakari P, Curbishley SM, Tomlinson JW, Hubscher SG, Reynolds GM, Aalto K, Anstee QM, Jalkanen S, Salmi M, Smith DJ, Day CP, Adams DH. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. J Clin Invest. 2015;125:501-520. [PMID: 25562318 DOI: 10.1172/jci73722] [Cited by in Crossref: 134] [Cited by in F6Publishing: 138] [Article Influence: 14.9] [Reference Citation Analysis]
192 Trovato FM, Catalano D, Musumeci G, Trovato GM. 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics. EPMA J. 2014;5:21. [PMID: 25937854 DOI: 10.1186/1878-5085-5-21] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
193 Mells JE, Fu PP, Kumar P, Smith T, Karpen SJ, Anania FA. Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis. J Nutr Biochem 2015;26:285-92. [PMID: 25577467 DOI: 10.1016/j.jnutbio.2014.11.002] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
194 Zhang X, Shen J, Man K, Chu ES, Yau TO, Sung JC, Go MY, Deng J, Lu L, Wong VW, Sung JJ, Farrell G, Yu J. CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis. J Hepatol 2014;61:1365-75. [PMID: 25048951 DOI: 10.1016/j.jhep.2014.07.006] [Cited by in Crossref: 130] [Cited by in F6Publishing: 124] [Article Influence: 14.4] [Reference Citation Analysis]
195 Kulkarni NM, Jaji MS, Shetty P, Kurhe YV, Chaudhary S, Vijaykant G, Raghul J, Vishwakarma SL, Rajesh BN, Mookkan J, Krishnan UM, Narayanan S. A novel animal model of metabolic syndrome with non-alcoholic fatty liver disease and skin inflammation. Pharm Biol 2015;53:1110-7. [PMID: 25430922 DOI: 10.3109/13880209.2014.960944] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
196 Wang DQ, Portincasa P, Neuschwander-Tetri BA. Steatosis in the liver. Compr Physiol 2013;3:1493-532. [PMID: 24265237 DOI: 10.1002/cphy.c130001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
197 Green CJ, Pramfalk C, Morten KJ, Hodson L. From whole body to cellular models of hepatic triglyceride metabolism: man has got to know his limitations. Am J Physiol Endocrinol Metab 2015;308:E1-20. [PMID: 25352434 DOI: 10.1152/ajpendo.00192.2014] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
198 Alwahsh SM, Xu M, Schultze FC, Wilting J, Mihm S, Raddatz D, Ramadori G. Combination of alcohol and fructose exacerbates metabolic imbalance in terms of hepatic damage, dyslipidemia, and insulin resistance in rats. PLoS One 2014;9:e104220. [PMID: 25101998 DOI: 10.1371/journal.pone.0104220] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 5.1] [Reference Citation Analysis]
199 Rosso N, Chavez-Tapia NC, Tiribelli C, Bellentani S. Translational approaches: From fatty liver to non-alcoholic steatohepatitis. World J Gastroenterol 2014; 20(27): 9038-9049 [PMID: 25083077 DOI: 10.3748/wjg.v20.i27.9038] [Cited by in F6Publishing: 26] [Reference Citation Analysis]
200 Souza-mello V. Nonalcoholic Steatohepatitis: Lessons from Different Diet-induced Animal Models. JDMDC 2014;1. [DOI: 10.15406/jdmdc.2014.01.00014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
201 Kalafati I, Borsa D, Dedoussis GVZ. The Genetics of Nonalcoholic Fatty Liver Disease: Role of Diet as a Modifying Factor. Curr Nutr Rep 2014;3:223-32. [DOI: 10.1007/s13668-014-0085-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
202 Nassir F, Ibdah JA. Role of mitochondria in nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15:8713-8742. [PMID: 24837835 DOI: 10.3390/ijms15058713] [Cited by in Crossref: 191] [Cited by in F6Publishing: 199] [Article Influence: 21.2] [Reference Citation Analysis]
203 Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci 2014;15:8591-638. [PMID: 24830559 DOI: 10.3390/ijms15058591] [Cited by in Crossref: 219] [Cited by in F6Publishing: 227] [Article Influence: 24.3] [Reference Citation Analysis]
204 Chheda TK, Shivakumar P, Sadasivan SK, Chanderasekharan H, Moolemath Y, Oommen AM, Madanahalli JR, Marikunte VV. Fast food diet with CCl4 micro-dose induced hepatic-fibrosis--a novel animal model. BMC Gastroenterol. 2014;14:89. [PMID: 24884574 DOI: 10.1186/1471-230x-14-89] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
205 Riordan JD, Nadeau JH. Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mamm Genome 2014;25:473-86. [PMID: 24802098 DOI: 10.1007/s00335-014-9521-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
206 Ritze Y, Bárdos G, Hubert A, Böhle M, Bischoff SC. Effect of tryptophan supplementation on diet-induced non-alcoholic fatty liver disease in mice. Br J Nutr 2014;112:1-7. [PMID: 24708895 DOI: 10.1017/S0007114514000440] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
207 Radwan MM, Radwan BM, Nandipati KC, Hunter WJ, Agrawal DK. Immunological and molecular basis of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. Expert Rev Clin Immunol. 2013;9:727-738. [PMID: 23971751 DOI: 10.1586/1744666x.2013.816484] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
208 Dowman JK, Hopkins LJ, Reynolds GM, Nikolaou N, Armstrong MJ, Shaw JC, Houlihan DD, Lalor PF, Tomlinson JW, Hübscher SG. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle. Am J Pathol. 2014;184:1550-1561. [PMID: 24650559 DOI: 10.1016/j.ajpath.2014.01.034] [Cited by in Crossref: 72] [Cited by in F6Publishing: 77] [Article Influence: 8.0] [Reference Citation Analysis]
209 Patterson E, O' Doherty RM, Murphy EF, Wall R, O' Sullivan O, Nilaweera K, Fitzgerald GF, Cotter PD, Ross RP, Stanton C. Impact of dietary fatty acids on metabolic activity and host intestinal microbiota composition in C57BL/6J mice. Br J Nutr. 2014;111:1905-1917. [PMID: 24555449 DOI: 10.1017/S0007114514000117] [Cited by in Crossref: 109] [Cited by in F6Publishing: 116] [Article Influence: 12.1] [Reference Citation Analysis]
210 Lonardo A, Caldwell SH, Loria P. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. Expert Review of Endocrinology & Metabolism 2014;5:403-23. [DOI: 10.1586/eem.10.5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
211 Yoo KD, Jun DW. Nonalcoholic Fatty Liver Disease: Lifestyle Modification. Korean J Med 2014;86:416. [DOI: 10.3904/kjm.2014.86.4.416] [Reference Citation Analysis]
212 Tabuchi M, Tomioka K, Hiramatsu M, Itoshima T, Tsukamoto I. Increase of the Plasma Trans-fatty Acid Level in Middle-aged Japanese Men with Non-alcoholic Fatty Liver Disease. JJSNFS 2014;67:137-143. [DOI: 10.4327/jsnfs.67.137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
213 Patel V, Sanyal AJ. Nonalcoholic Fatty Liver Disease. Liver Immunology 2014. [DOI: 10.1007/978-3-319-02096-9_23] [Reference Citation Analysis]
214 Takahashi Y, Soejima Y, Fukusato T. Animal Models for Nonalcoholic Fatty Liver Disease. Integrative Weight Management 2014. [DOI: 10.1007/978-1-4939-0548-5_6] [Reference Citation Analysis]
215 Ma X, Lin L, Yue J, Pradhan G, Qin G, Minze LJ, Wu H, Sheikh-Hamad D, Smith CW, Sun Y. Ghrelin receptor regulates HFCS-induced adipose inflammation and insulin resistance. Nutr Diabetes 2013;3:e99. [PMID: 24366371 DOI: 10.1038/nutd.2013.41] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
216 Petta S, Marchesini G, Caracausi L, Macaluso FS, Cammà C, Ciminnisi S, Cabibi D, Porcasi R, Craxì A, Di Marco V. Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. J Hepatol 2013;59:1169-76. [PMID: 23933265 DOI: 10.1016/j.jhep.2013.07.037] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
217 Quintero P, Arrese M. Nuclear control of inflammation and fibrosis in nonalcoholic steatohepatitis: therapeutic potential of dual peroxisome proliferator-activated receptor alpha/delta agonism. Hepatology 2013;58:1881-4. [PMID: 23787705 DOI: 10.1002/hep.26582] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
218 Jun DW. [The role of diet in non-alcoholic fatty liver disease]. Korean J Gastroenterol 2013;61:243-51. [PMID: 23756665 DOI: 10.4166/kjg.2013.61.5.243] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
219 Tong X, Yin L. Circadian rhythms in liver physiology and liver diseases. Compr Physiol 2013;3:917-40. [PMID: 23720334 DOI: 10.1002/cphy.c120017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
220 Imajo K, Yoneda M, Kessoku T, Ogawa Y, Maeda S, Sumida Y, Hyogo H, Eguchi Y, Wada K, Nakajima A. Rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Int J Mol Sci. 2013;14:21833-21857. [PMID: 24192824 DOI: 10.3390/ijms141121833] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 6.4] [Reference Citation Analysis]
221 Zámbó V, Simon-Szabó L, Szelényi P, Kereszturi &, Bánhegyi G, Csala M. Lipotoxicity in the liver. World J Hepatol 2013; 5(10): 550-557 [PMID: 24179614 DOI: 10.4254/wjh.v5.i10.550] [Cited by in Crossref: 115] [Cited by in F6Publishing: 121] [Article Influence: 11.5] [Reference Citation Analysis]
222 Peluso MEM, Munnia A, Tarocchi M, Arciello M, Balsano C, Giese RW, Galli A. Exocycilic DNA Adducts in a Murine Model of Non-alcoholic Steatohepatitis. J Carcinog Mutagen 2013;2013:003. [PMID: 31528500 DOI: 10.4172/2157-2518.S3-003] [Reference Citation Analysis]
223 Dissard R, Klein J, Caubet C, Breuil B, Siwy J, Hoffman J, Sicard L, Ducassé L, Rascalou S, Payre B, Buléon M, Mullen W, Mischak H, Tack I, Bascands JL, Buffin-Meyer B, Schanstra JP. Long term metabolic syndrome induced by a high fat high fructose diet leads to minimal renal injury in C57BL/6 mice. PLoS One 2013;8:e76703. [PMID: 24098551 DOI: 10.1371/journal.pone.0076703] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
224 Clapper JR, Hendricks MD, Gu G, Wittmer C, Dolman CS, Herich J, Athanacio J, Villescaz C, Ghosh SS, Heilig JS, Lowe C, Roth JD. Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. Am J Physiol Gastrointest Liver Physiol 2013;305:G483-95. [PMID: 23886860 DOI: 10.1152/ajpgi.00079.2013] [Cited by in Crossref: 174] [Cited by in F6Publishing: 168] [Article Influence: 17.4] [Reference Citation Analysis]
225 Dowman JK, Hopkins LJ, Reynolds GM, Armstrong MJ, Nasiri M, Nikolaou N, van Houten EL, Visser JA, Morgan SA, Lavery GG. Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. Endocrinology. 2013;154:4536-4547. [PMID: 24080367 DOI: 10.1210/en.2013-1592] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 5.6] [Reference Citation Analysis]
226 de Castro UG, dos Santos RA, Silva ME, de Lima WG, Campagnole-Santos MJ, Alzamora AC. Age-dependent effect of high-fructose and high-fat diets on lipid metabolism and lipid accumulation in liver and kidney of rats. Lipids Health Dis 2013;12:136. [PMID: 24044579 DOI: 10.1186/1476-511X-12-136] [Cited by in Crossref: 67] [Cited by in F6Publishing: 75] [Article Influence: 6.7] [Reference Citation Analysis]
227 Liou J, Tuazon MA, Burdzy A, Henderson GC. Moderate compared to low dietary intake of trans-fatty acids impairs strength of old and aerobic capacity of young SAMP8 mice in both sexes. Lipids 2013;48:1135-43. [PMID: 23955555 DOI: 10.1007/s11745-013-3831-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
228 Longato L. Non-alcoholic fatty liver disease (NAFLD): a tale of fat and sugar? Fibrogenesis Tissue Repair. 2013;6:14. [PMID: 23866299 DOI: 10.1186/1755-1536-6-14] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
229 Macaluso FS, Maida M, Minissale MG, Li Vigni T, Attardo S, Orlando E, Petta S. Metabolic factors and chronic hepatitis C: a complex interplay. Biomed Res Int. 2013;2013:564645. [PMID: 23956991 DOI: 10.1155/2013/564645] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
230 Tyson GL, Richardson PA, White DL, Kuzniarek J, Ramsey DJ, Tavakoli-Tabasi S, El-Serag HB. Dietary fructose intake and severity of liver disease in hepatitis C virus-infected patients. J Clin Gastroenterol 2013;47:545-52. [PMID: 23426443 DOI: 10.1097/MCG.0b013e31827244d9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
231 Hijmans BS, Grefhorst A, Oosterveer MH, Groen AK. Zonation of glucose and fatty acid metabolism in the liver: mechanism and metabolic consequences. Biochimie. 2014;96:121-129. [PMID: 23792151 DOI: 10.1016/j.biochi.2013.06.007] [Cited by in Crossref: 102] [Cited by in F6Publishing: 110] [Article Influence: 10.2] [Reference Citation Analysis]
232 Chen A, Tang Y, Davis V, Hsu FF, Kennedy SM, Song H, Turk J, Brunt EM, Newberry EP, Davidson NO. Liver fatty acid binding protein (L-Fabp) modulates murine stellate cell activation and diet-induced nonalcoholic fatty liver disease. Hepatology 2013;57:2202-12. [PMID: 23401290 DOI: 10.1002/hep.26318] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 5.5] [Reference Citation Analysis]
233 Mahady SE, George J. The future liver of the Asia pacific: fatter and firmer from more fructose and fortune? J Clin Exp Hepatol 2013;3:106-13. [PMID: 25755484 DOI: 10.1016/j.jceh.2012.10.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
234 Song M, Schuschke DA, Zhou Z, Chen T, Shi X, Zhang J, Zhang X, Pierce WM Jr, Johnson WT, Vos MB, McClain CJ. Modest fructose beverage intake causes liver injury and fat accumulation in marginal copper deficient rats. Obesity (Silver Spring) 2013;21:1669-75. [PMID: 23512597 DOI: 10.1002/oby.20380] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
235 Ushio M, Nishio Y, Sekine O, Nagai Y, Maeno Y, Ugi S, Yoshizaki T, Morino K, Kume S, Kashiwagi A. Ezetimibe prevents hepatic steatosis induced by a high-fat but not a high-fructose diet. Am J Physiol Endocrinol Metab. 2013;305:E293-E304. [PMID: 23715726 DOI: 10.1152/ajpendo.00442.2012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
236 Podrini C, Cambridge EL, Lelliott CJ, Carragher DM, Estabel J, Gerdin AK, Karp NA, Scudamore CL, Ramirez-Solis R, White JK; Sanger Mouse Genetics Project. High-fat feeding rapidly induces obesity and lipid derangements in C57BL/6N mice. Mamm Genome 2013;24:240-51. [PMID: 23712496 DOI: 10.1007/s00335-013-9456-0] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
237 Oddy WH, Herbison CE, Jacoby P, Ambrosini GL, O'Sullivan TA, Ayonrinde OT, Olynyk JK, Black LJ, Beilin LJ, Mori TA, Hands BP, Adams LA. The Western dietary pattern is prospectively associated with nonalcoholic fatty liver disease in adolescence. Am J Gastroenterol 2013;108:778-85. [PMID: 23545714 DOI: 10.1038/ajg.2013.95] [Cited by in Crossref: 179] [Cited by in F6Publishing: 178] [Article Influence: 17.9] [Reference Citation Analysis]
238 Leclercq IA. Emerging Concepts on the Pathogenesis of Non-Alcoholic Steatohepatitis (NASH). Non-Alcoholic Fatty Liver Disease 2013. [DOI: 10.1002/9781118556153.ch5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
239 Perito ER, Rodriguez LA, Lustig RH. Dietary treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2013;29:170-6. [PMID: 23283181 DOI: 10.1097/MOG.0b013e32835ca11d] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
240 Liu Y, Meyer C, Xu C, Weng H, Hellerbrand C, ten Dijke P, Dooley S. Animal models of chronic liver diseases. Am J Physiol Gastrointest Liver Physiol 2013;304:G449-68. [PMID: 23275613 DOI: 10.1152/ajpgi.00199.2012] [Cited by in Crossref: 145] [Cited by in F6Publishing: 140] [Article Influence: 14.5] [Reference Citation Analysis]
241 Basaranoglu M, Basaranoglu G, Sentürk H. From fatty liver to fibrosis: A tale of “second hit”. World J Gastroenterol 2013; 19(8): 1158-1165 [PMID: 23483818 DOI: 10.3748/wjg.v19.i8.1158] [Cited by in CrossRef: 110] [Cited by in F6Publishing: 119] [Article Influence: 11.0] [Reference Citation Analysis]
242 Basaranoglu M, Basaranoglu G, Sabuncu T, Sentürk H. Fructose as a key player in the development of fatty liver disease. World J Gastroenterol 2013; 19(8): 1166-1172 [PMID: 23482247 DOI: 10.3748/wjg.v19.i8.1166] [Cited by in CrossRef: 151] [Cited by in F6Publishing: 158] [Article Influence: 15.1] [Reference Citation Analysis]
243 Samson SL, Bajaj M. Potential of incretin-based therapies for non-alcoholic fatty liver disease. J Diabetes Complications. 2013;27:401-406. [PMID: 23352496 DOI: 10.1016/j.jdiacomp.2012.12.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
244 Li JV, Saric J, Yap IKS, Utzinger J, Holmes E. Metabonomic investigations of age- and batch-related variations in female NMRI mice using proton nuclear magnetic resonance spectroscopy. Mol BioSyst 2013;9:3155. [DOI: 10.1039/c3mb70215d] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
245 Erario M, Younossi ZM. Nonalcoholic Fatty Liver Disease in Adults: The Impact of Diet and Other Therapeutic Interventions on Clinical and Histological Outcomes. Diet Quality 2013. [DOI: 10.1007/978-1-4614-7315-2_4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
246 Karim S, Adams DH, Lalor PF. Hepatic expression and cellular distribution of the glucose transporter family. World J Gastroenterol 2012; 18(46): 6771-6781 [PMID: 23239915 DOI: 10.3748/wjg.v18.i46.6771] [Cited by in CrossRef: 106] [Cited by in F6Publishing: 109] [Article Influence: 9.6] [Reference Citation Analysis]
247 Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. Endocr Rev. 2013;34:84-129. [PMID: 23238855 DOI: 10.1210/er.2012-1009] [Cited by in Crossref: 157] [Cited by in F6Publishing: 165] [Article Influence: 14.3] [Reference Citation Analysis]
248 Di Minno MND, Russolillo A, Lupoli R, Ambrosino P, Di Minno A, Tarantino G. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol 2012; 18(41): 5839-5847 [PMID: 23139599 DOI: 10.3748/wjg.v18.i41.5839] [Cited by in CrossRef: 114] [Cited by in F6Publishing: 121] [Article Influence: 10.4] [Reference Citation Analysis]
249 Anty R, Marjoux S, Iannelli A, Patouraux S, Schneck AS, Bonnafous S, Gire C, Amzolini A, Ben-Amor I, Saint-Paul MC, Mariné-Barjoan E, Pariente A, Gugenheim J, Gual P, Tran A. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol 2012;57:1090-6. [PMID: 22820478 DOI: 10.1016/j.jhep.2012.07.014] [Cited by in Crossref: 103] [Cited by in F6Publishing: 100] [Article Influence: 9.4] [Reference Citation Analysis]
250 Schugar RC, Crawford PA. Low-carbohydrate ketogenic diets, glucose homeostasis, and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2012;15:374-80. [PMID: 22617564 DOI: 10.1097/MCO.0b013e3283547157] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 6.1] [Reference Citation Analysis]
251 Neuschwander-Tetri BA, Ford DA, Acharya S, Gilkey G, Basaranoglu M, Tetri LH, Brunt EM. Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools. Lipids 2012;47:941-50. [PMID: 22923371 DOI: 10.1007/s11745-012-3709-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
252 Collison KS, Zaidi MZ, Saleh SM, Inglis A, Mondreal R, Makhoul NJ, Bakheet R, Burrows J, Milgram NW, Al-Mohanna FA. Effect of trans-fat, fructose and monosodium glutamate feeding on feline weight gain, adiposity, insulin sensitivity, adipokine and lipid profile. Br J Nutr 2011;106:218-26. [PMID: 21429276 DOI: 10.1017/S000711451000588X] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
253 Kawanishi N, Yano H, Mizokami T, Takahashi M, Oyanagi E, Suzuki K. Exercise training attenuates hepatic inflammation, fibrosis and macrophage infiltration during diet induced-obesity in mice. Brain, Behavior, and Immunity 2012;26:931-41. [DOI: 10.1016/j.bbi.2012.04.006] [Cited by in Crossref: 84] [Cited by in F6Publishing: 84] [Article Influence: 7.6] [Reference Citation Analysis]
254 Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:837-58. [PMID: 22446927 DOI: 10.1016/j.cgh.2012.03.011] [Cited by in Crossref: 177] [Cited by in F6Publishing: 155] [Article Influence: 16.1] [Reference Citation Analysis]
255 Du L, Heaney AP. Regulation of adipose differentiation by fructose and GluT5. Mol Endocrinol 2012;26:1773-82. [PMID: 22827929 DOI: 10.1210/me.2012-1122] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
256 Colak Y, Tuncer I, Senates E, Ozturk O, Doganay L, Yilmaz Y. Nonalcoholic Fatty Liver Disease: A Nutritional Approach. Metabolic Syndrome and Related Disorders 2012;10:161-6. [DOI: 10.1089/met.2011.0145] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
257 Yilmaz Y. Review article: fructose in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012;35:1135-44. [PMID: 22469071 DOI: 10.1111/j.1365-2036.2012.05080.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 4.5] [Reference Citation Analysis]
258 Farrell GC, van Rooyen D, Gan L, Chitturi S. NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver. 2012;6:149-171. [PMID: 22570745 DOI: 10.5009/gnl.2012.6.2.149] [Cited by in Crossref: 274] [Cited by in F6Publishing: 285] [Article Influence: 24.9] [Reference Citation Analysis]
259 Kim YO, Schuppan D. When GLP-1 hits the liver: a novel approach for insulin resistance and NASH. Am J Physiol Gastrointest Liver Physiol 2012;302:G759-61. [PMID: 22383493 DOI: 10.1152/ajpgi.00078.2012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
260 Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, Erickson MR, Napora J, Parkes DG, Roth JD. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 2012;302:G762-72. [PMID: 22268099 DOI: 10.1152/ajpgi.00476.2011] [Cited by in Crossref: 171] [Cited by in F6Publishing: 178] [Article Influence: 15.5] [Reference Citation Analysis]
261 Kopec KL, Burns D. Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract. 2011;26:565-576. [PMID: 21947639 DOI: 10.1177/0884533611419668] [Cited by in Crossref: 73] [Cited by in F6Publishing: 79] [Article Influence: 6.6] [Reference Citation Analysis]
262 Barrios-Ramos JP, Garduño-Siciliano L, Loredo M, Chamorro-Cevallos G, Jaramillo-Flores ME. The effect of cocoa, soy, oats and fish oil on metabolic syndrome in rats. J Sci Food Agric 2012;92:2349-57. [PMID: 22430394 DOI: 10.1002/jsfa.5637] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
263 Schattenberg JM, Schuppan D. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr Opin Lipidol 2011;22:479-88. [PMID: 22002020 DOI: 10.1097/MOL.0b013e32834c7cfc] [Cited by in Crossref: 87] [Cited by in F6Publishing: 94] [Article Influence: 7.9] [Reference Citation Analysis]
264 McCarthy EM, Rinella ME. The role of diet and nutrient composition in nonalcoholic Fatty liver disease. J Acad Nutr Diet. 2012;112:401-409. [PMID: 22717200 DOI: 10.1016/j.jada.2011.10.007] [Cited by in Crossref: 109] [Cited by in F6Publishing: 97] [Article Influence: 9.9] [Reference Citation Analysis]
265 Alisi A, Pastore A, Ceccarelli S, Panera N, Gnani D, Bruscalupi G, Massimi M, Tozzi G, Piemonte F, Nobili V. Emodin prevents intrahepatic fat accumulation, inflammation and redox status imbalance during diet-induced hepatosteatosis in rats. Int J Mol Sci. 2012;13:2276-2289. [PMID: 22408453 DOI: 10.3390/ijms13022276] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
266 Bremer AA, Mietus-Snyder M, Lustig RH. Toward a unifying hypothesis of metabolic syndrome. Pediatrics 2012;129:557-70. [PMID: 22351884 DOI: 10.1542/peds.2011-2912] [Cited by in Crossref: 115] [Cited by in F6Publishing: 122] [Article Influence: 10.5] [Reference Citation Analysis]
267 Alisi A, Bruscalupi G, Pastore A, Petrini S, Panera N, Massimi M, Tozzi G, Leoni S, Piemonte F, Nobili V. Redox homeostasis and posttranslational modifications/activity of phosphatase and tensin homolog in hepatocytes from rats with diet-induced hepatosteatosis. The Journal of Nutritional Biochemistry 2012;23:169-78. [DOI: 10.1016/j.jnutbio.2010.11.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
268 Mells JE, Fu PP, Sharma S, Olson D, Cheng L, Handy JA, Saxena NK, Sorescu D, Anania FA. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol 2012;302:G225-35. [PMID: 22038829 DOI: 10.1152/ajpgi.00274.2011] [Cited by in Crossref: 148] [Cited by in F6Publishing: 144] [Article Influence: 13.5] [Reference Citation Analysis]
269 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 11] [Article Influence: 1.0] [Reference Citation Analysis]
270 Pollock NK, Bundy V, Kanto W, Davis CL, Bernard PJ, Zhu H, Gutin B, Dong Y. Greater fructose consumption is associated with cardiometabolic risk markers and visceral adiposity in adolescents. J Nutr. 2012;142:251-257. [PMID: 22190023 DOI: 10.3945/jn.111.150219] [Cited by in Crossref: 84] [Cited by in F6Publishing: 114] [Article Influence: 7.0] [Reference Citation Analysis]
271 Caldwell SH, Argo CK, Al‐osaimi AMS. Nonalcoholic Fatty Liver Disease. Schiff's Diseases of the Liver 2011. [DOI: 10.1002/9781119950509.ch32] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
272 Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci. 2011;48:97-113. [PMID: 21875310 DOI: 10.3109/10408363.2011.596521] [Cited by in Crossref: 198] [Cited by in F6Publishing: 210] [Article Influence: 16.5] [Reference Citation Analysis]
273 Collison KS, Zaidi MZ, Saleh SM, Makhoul NJ, Inglis A, Burrows J, Araujo JA, Al-Mohanna FA. Nutrigenomics of hepatic steatosis in a feline model: effect of monosodium glutamate, fructose, and Trans-fat feeding. Genes Nutr 2012;7:265-80. [PMID: 22144172 DOI: 10.1007/s12263-011-0261-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
274 Qiu L, Lin J, Xu F, Gao Y, Zhang C, Liu Y, Luo Y, Yang JY. Inhibition of aldose reductase activates hepatic peroxisome proliferator-activated receptor-α and ameliorates hepatosteatosis in diabetic db/db mice. Exp Diabetes Res 2012;2012:789730. [PMID: 22110479 DOI: 10.1155/2012/789730] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
275 Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A, Masuoko H, Gores G. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011;301:G825-34. [PMID: 21836057 DOI: 10.1152/ajpgi.00145.2011] [Cited by in Crossref: 293] [Cited by in F6Publishing: 272] [Article Influence: 24.4] [Reference Citation Analysis]
276 Mencin AA, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Pediatr Clin North Am. 2011;58:1375-1392, x. [PMID: 22093857 DOI: 10.1016/j.pcl.2011.09.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
277 Kohli R, Feldstein AE. NASH animal models: are we there yet? J Hepatol 2011;55:941-3. [PMID: 21708199 DOI: 10.1016/j.jhep.2011.04.010] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
278 Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One. 2011;6:e25269. [PMID: 21957486 DOI: 10.1371/journal.pone.0025269] [Cited by in Crossref: 166] [Cited by in F6Publishing: 187] [Article Influence: 13.8] [Reference Citation Analysis]
279 Jeyakumar SM, Prashant A, Rani KS, Laxmi R, Vani A, Kumar PU, Vajreswari A. Chronic Consumption of <i>trans-</i>Fat-Rich Diet Increases Hepatic Cholesterol Levels and Impairs Muscle Insulin Sensitivity without Leading to Hepatic Steatosis and Hypertriglyceridemia in Female Fischer Rats. Ann Nutr Metab 2011;58:272-80. [DOI: 10.1159/000331215] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
280 Berglund ED, Lustig DG, Baheza RA, Hasenour CM, Lee-Young RS, Donahue EP, Lynes SE, Swift LL, Charron MJ, Damon BM, Wasserman DH. Hepatic glucagon action is essential for exercise-induced reversal of mouse fatty liver. Diabetes 2011;60:2720-9. [PMID: 21885872 DOI: 10.2337/db11-0455] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
281 Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: An overview of the epidemiological evidence. World J Gastroenterol 2011; 17(29): 3377-3389 [PMID: 21876630 DOI: 10.3748/wjg.v17.i29.3377] [Cited by in CrossRef: 179] [Cited by in F6Publishing: 195] [Article Influence: 14.9] [Reference Citation Analysis]
282 Scaglioni F, Ciccia S, Marino M, Bedogni G, Bellentani S. ASH and NASH. Dig Dis 2011;29:202-10. [PMID: 21734385 DOI: 10.1159/000323886] [Cited by in Crossref: 51] [Cited by in F6Publishing: 57] [Article Influence: 4.3] [Reference Citation Analysis]
283 Anania FA. Non-alcoholic fatty liver disease and fructose: bad for us, better for mice. J Hepatol 2011;55:218-20. [PMID: 21338637 DOI: 10.1016/j.jhep.2011.01.029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
284 Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism 2011;13:692-702. [DOI: 10.1111/j.1463-1326.2011.01403.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 90] [Article Influence: 7.1] [Reference Citation Analysis]
285 Maher JJ. New insights from rodent models of fatty liver disease. Antioxid Redox Signal 2011;15:535-50. [PMID: 21126212 DOI: 10.1089/ars.2010.3749] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
286 . References. A Guide to Obesity and the Metabolic Syndrome 2011. [DOI: 10.1201/b10790-15] [Reference Citation Analysis]
287 Stanton MC, Chen SC, Jackson JV, Rojas-Triana A, Kinsley D, Cui L, Fine JS, Greenfeder S, Bober LA, Jenh CH. Inflammatory Signals shift from adipose to liver during high fat feeding and influence the development of steatohepatitis in mice. J Inflamm (Lond). 2011;8:8. [PMID: 21410952 DOI: 10.1186/1476-9255-8-8] [Cited by in Crossref: 92] [Cited by in F6Publishing: 97] [Article Influence: 7.7] [Reference Citation Analysis]
288 Silbernagel G, Machann J, Unmuth S, Schick F, Stefan N, Häring HU, Fritsche A. Effects of 4-week very-high-fructose/glucose diets on insulin sensitivity, visceral fat and intrahepatic lipids: an exploratory trial. Br J Nutr 2011;106:79-86. [DOI: 10.1017/s000711451000574x] [Cited by in Crossref: 120] [Cited by in F6Publishing: 149] [Article Influence: 10.0] [Reference Citation Analysis]
289 Bendsen NT, Chabanova E, Thomsen HS, Larsen TM, Newman JW, Stender S, Dyerberg J, Haugaard SB, Astrup A. Effect of trans fatty acid intake on abdominal and liver fat deposition and blood lipids: a randomized trial in overweight postmenopausal women. Nutr Diabetes 2011;1:e4. [PMID: 23154296 DOI: 10.1038/nutd.2010.4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
290 Huang D, Dhawan T, Young S, Yong WH, Boros LG, Heaney AP. Fructose impairs glucose-induced hepatic triglyceride synthesis. Lipids Health Dis 2011;10:20. [PMID: 21261970 DOI: 10.1186/1476-511X-10-20] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
291 Liu WH, Lin CC, Wang ZH, Mong MC, Yin MC. Effects of protocatechuic acid on trans fat induced hepatic steatosis in mice. J Agric Food Chem. 2010;58:10247-10252. [PMID: 20799701 DOI: 10.1021/jf102379n] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
292 Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2011;8:35-44. [PMID: 21119613 DOI: 10.1038/nrgastro.2010.191] [Cited by in Crossref: 333] [Cited by in F6Publishing: 326] [Article Influence: 27.8] [Reference Citation Analysis]
293 Marchesini G, Nuccitelli C, Centis E, Di Domizio S, Suppini A, Marzocchi R, Grave RD. Behavioral Aspects of Nonalcoholic Fatty Liver Disease: Diet, Causes, and Treatment. Handbook of Behavior, Food and Nutrition 2011. [DOI: 10.1007/978-0-387-92271-3_119] [Reference Citation Analysis]
294 Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010;52:1836-46. [PMID: 21038418 DOI: 10.1002/hep.24001] [Cited by in Crossref: 1511] [Cited by in F6Publishing: 1473] [Article Influence: 116.2] [Reference Citation Analysis]
295 Chen CL, Tetri LH, Neuschwander-Tetri BA, Huang SS, Huang JS. A mechanism by which dietary trans fats cause atherosclerosis. J Nutr Biochem 2011;22:649-55. [PMID: 21036587 DOI: 10.1016/j.jnutbio.2010.05.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
296 Neuschwander-Tetri BA. Nontriglyceride hepatic lipotoxicity: the new paradigm for the pathogenesis of NASH. Curr Gastroenterol Rep. 2010;12:49-56. [PMID: 20425484 DOI: 10.1007/s11894-009-0083-6] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 3.6] [Reference Citation Analysis]
297 Lustig RH. Fructose: metabolic, hedonic, and societal parallels with ethanol. J Am Diet Assoc 2010;110:1307-21. [PMID: 20800122 DOI: 10.1016/j.jada.2010.06.008] [Cited by in Crossref: 204] [Cited by in F6Publishing: 172] [Article Influence: 15.7] [Reference Citation Analysis]
298 Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V, Tang PH, Miles L, Miles MV, Balistreri WF, Woods SC, Seeley RJ. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 2010;52:934-44. [PMID: 20607689 DOI: 10.1002/hep.23797] [Cited by in Crossref: 267] [Cited by in F6Publishing: 258] [Article Influence: 20.5] [Reference Citation Analysis]
299 Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-84. [PMID: 20494470 DOI: 10.1016/j.jhep.2010.04.008] [Cited by in Crossref: 711] [Cited by in F6Publishing: 738] [Article Influence: 54.7] [Reference Citation Analysis]
300 Obara N, Fukushima K, Ueno Y, Wakui Y, Kimura O, Tamai K, Kakazu E, Inoue J, Kondo Y, Ogawa N, Sato K, Tsuduki T, Ishida K, Shimosegawa T. Possible involvement and the mechanisms of excess trans-fatty acid consumption in severe NAFLD in mice. J Hepatol 2010;53:326-34. [PMID: 20462650 DOI: 10.1016/j.jhep.2010.02.029] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 5.0] [Reference Citation Analysis]
301 Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010;52:774-88. [PMID: 20683968 DOI: 10.1002/hep.23719] [Cited by in Crossref: 706] [Cited by in F6Publishing: 684] [Article Influence: 54.3] [Reference Citation Analysis]
302 Behari J, Chalasani N. Challenging the Rodent Hegemony. The American Journal of Pathology 2010;177:10-12. [DOI: 10.2353/ajpath.2010.100410] [Reference Citation Analysis]
303 Dong Q, Yang K, Wong SM, O'Brien PJ. Hepatocyte or serum albumin protein carbonylation by oxidized fructose metabolites: Glyceraldehyde or glycolaldehyde as endogenous toxins? Chem Biol Interact 2010;188:31-7. [PMID: 20561512 DOI: 10.1016/j.cbi.2010.06.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
304 Tappy L, Lê KA, Tran C, Paquot N. Fructose and metabolic diseases: new findings, new questions. Nutrition 2010;26:1044-9. [PMID: 20471804 DOI: 10.1016/j.nut.2010.02.014] [Cited by in Crossref: 240] [Cited by in F6Publishing: 252] [Article Influence: 18.5] [Reference Citation Analysis]
305 Basaranoglu M, Kayacetin S, Yilmaz N, Kayacetin E, Tarcin O, Sonsuz A. Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16(18): 2223-2226 [PMID: 20458758 DOI: 10.3748/wjg.v16.i18.2223] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 46] [Article Influence: 3.3] [Reference Citation Analysis]
306 Neuschwander-Tetri BA. NASH: Thiazolidinediones for NASH--one pill doesn't fix everything. Nat Rev Gastroenterol Hepatol 2010;7:243-4. [PMID: 20442730 DOI: 10.1038/nrgastro.2010.50] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
307 Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 2010;7:251-64. [PMID: 20368739 DOI: 10.1038/nrgastro.2010.41] [Cited by in Crossref: 493] [Cited by in F6Publishing: 503] [Article Influence: 37.9] [Reference Citation Analysis]
308 Machado RM, Stefano JT, Oliveira CP, Mello ES, Ferreira FD, Nunes VS, de Lima VM, Quintão EC, Catanozi S, Nakandakare ER, Lottenberg AM. Intake of trans fatty acids causes nonalcoholic steatohepatitis and reduces adipose tissue fat content. J Nutr 2010;140:1127-32. [PMID: 20357081 DOI: 10.3945/jn.109.117937] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 4.3] [Reference Citation Analysis]
309 Sullivan S. Implications of diet on nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2010;26:160-4. [PMID: 20010099 DOI: 10.1097/MOG.0b013e3283358a58] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 3.4] [Reference Citation Analysis]
310 Wallace SK, Mozaffarian D. Trans-fatty acids and nonlipid risk factors. Curr Atheroscler Rep 2009;11:423-33. [PMID: 19852883 DOI: 10.1007/s11883-009-0064-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
311 Tappy L, Lê KA. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev 2010;90:23-46. [PMID: 20086073 DOI: 10.1152/physrev.00019.2009] [Cited by in Crossref: 768] [Cited by in F6Publishing: 806] [Article Influence: 59.1] [Reference Citation Analysis]
312 Collison KS, Maqbool ZM, Inglis AL, Makhoul NJ, Saleh SM, Bakheet RH, Al-Johi MA, Al-Rabiah RK, Zaidi MZ, Al-Mohanna FA. Effect of dietary monosodium glutamate on HFCS-induced hepatic steatosis: expression profiles in the liver and visceral fat. Obesity (Silver Spring) 2010;18:1122-34. [PMID: 20111022 DOI: 10.1038/oby.2009.502] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
313 Schattenberg JM, Schuchmann M. Diabetes and apoptosis: liver. Apoptosis 2009;14:1459-71. [PMID: 19544096 DOI: 10.1007/s10495-009-0366-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
314 Ko JS. Nonalcoholic Fatty Liver Disease. Korean J Gastroenterol 2010;56:6. [DOI: 10.4166/kjg.2010.56.1.6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
315 Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev. 2010;11:430-445. [PMID: 19845871 DOI: 10.1111/j.1467-789x.2009.00657.x] [Cited by in Crossref: 126] [Cited by in F6Publishing: 133] [Article Influence: 9.0] [Reference Citation Analysis]
316 Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009;41:615-25. [PMID: 19223251 DOI: 10.1016/j.dld.2009.01.004] [Cited by in Crossref: 188] [Cited by in F6Publishing: 192] [Article Influence: 13.4] [Reference Citation Analysis]
317 Brunt EM. What's in a NAme? Hepatology 2009;50:663-7. [PMID: 19585620 DOI: 10.1002/hep.23070] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
318 Angelopoulos TJ, Lowndes J, Zukley L, Melanson KJ, Nguyen V, Huffman A, Rippe JM. The effect of high-fructose corn syrup consumption on triglycerides and uric acid. J Nutr 2009;139:1242S-5S. [PMID: 19403709 DOI: 10.3945/jn.108.098194] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 3.8] [Reference Citation Analysis]
319 Collison KS, Saleh SM, Bakheet RH, Al-Rabiah RK, Inglis AL, Makhoul NJ, Maqbool ZM, Zaidi MZ, Al-Johi MA, Al-Mohanna FA. Diabetes of the liver: the link between nonalcoholic fatty liver disease and HFCS-55. Obesity (Silver Spring) 2009;17:2003-13. [PMID: 19282820 DOI: 10.1038/oby.2009.58] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 4.1] [Reference Citation Analysis]
320 Collison KS, Maqbool Z, Saleh SM, Inglis A, Makhoul NJ, Bakheet R, Al-Johi M, Al-Rabiah R, Zaidi MZ, Al-Mohanna FA. Effect of dietary monosodium glutamate on trans fat-induced nonalcoholic fatty liver disease. J Lipid Res 2009;50:1521-37. [PMID: 19001666 DOI: 10.1194/jlr.M800418-JLR200] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 4.1] [Reference Citation Analysis]